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LIST OF ABBREVIATIONS 
 
 
7AAD:   7 amino-actinomycin D 
cDNA:   complementary DNA 
CMV:   cytomegalovirus 
cPPT:   central polypurine tract 
EBNA:  Epstein-Barr nuclear antigen 
EBV:   Epstein-Barr virus 
EF1α:   elongation factor 1α 
FACS:   fluorescence-activated cell sorter 
FCS:   fetal calf serum 
FLIP:   FLICE inhibitory molecule 
GFP:   green fluorescent protein 
HIV:   human immune-deficiency virus 
IRES:   internal ribosome entry site 
LMP-1:  latent membrane protein 1 
LPD:   lymphoproliferative disease 
LTR:   long terminal repeat 
MFI:   mean fluorescence intensity 
MIB-1:   monoclonal antibody for Ki-67 
M-MLV:  Moloney murine leukemia virus 
MOI:   multiplicity of infection 
PALS:   periarteriolar lymphoid sheath 
PBL:   peripheral blood lymphocyte 
PBS:   phosphate-buffered saline 
PCR:   polymerase chain reaction 
SCID:   severe combined immune deficiency 
SEM:   standard error of mean 
SIN:   self inactivating 
scFv:  single-chain variable fragment 
TLR:   Toll-like receptor 
VSV-G:  vesicular stomatitis virus G-protein 
WPRE/WHV:  Woodchuck-hepatitis virus post-transcriptional responsive element 
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GENERAL INTRODUCTION 
 
 In a simplistic way innate immunity in vertebrates fights cellular intruders (bacteria, 
fungi, parasites), while acquired immunity is more specialized for subcellular pathogens 
(viruses). This is in part supported by the complex relationship between viruses and 
lymphocytes. There are numerous known receptor-ligand pairs that allow for specific and 
strong interaction between viruses and lymphocytes. Depending on the context i.e. the actual 
status of continuous co-evolution such physical connections may help efficient viral infection 
of lymphocytes or specific immune recognition of viruses.  
 Both lymphocytes and viruses display extensive genetic variability. The rapid and 
mutation-prone replication of viruses has been such an evolutionary demand that perhaps 
only gene-rearrangement processes restricted to antigen-receptor bearing lymphocytes could 
bring back balance for long-lived and genetically otherwise stable vertebrates in terms of co-
evolution. In most cases viruses infect non-lymphoid cells, but elicit immune responses 
dominated by lymphoid cells. However, in the cases investigated here it is a part of the 
lymphoid cell population that becomes either transformed by wild-type or transduced by 
artificial viruses. Having said these it is especially exciting to investigate certain virus-
triggered lymphoid diseases and to utilise domesticated viral vectors for research purposes in 
lymphocytes.  
 
 
AIMS 
 
1. In vivo modelling of the post-transplantation lymphoproliferative disease (PTLD) triggered 
by endogenous EBV-reactivation in human primary B-lymphocytes in a human-mouse (hu-
SCID) chimera system. 
 
2. Standardisation of the chimeric PTLD model system by performing an in vivo 
superinfection and confirming the dominance of the introduced EBV strain. 
 
3. Establishment of human primary B cell monoculture system allowing for efficient lentiviral 
transduction, investigation of gene transfer efficiency by marker gene expression (GFP). 
 
4. Transduction of representative intracellular (vFLIP) and secreted (IL4) transgenes in 
parallel with GFP, investigation of their expression or activity in functional assays. 
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SECTION I. 
 
Establishment and fine-tuning of the EBV-associated post-
transplantation lymphoproliferative disease model system 
 
1.1 Summary  
Our purpose was to establish a reproducible chimera model to observe tumours similar 
to human post-transplantation lymphoproliferative disease (LPD). First we followed the 
original protocol by injecting Epstein-Barr virus positive (EBV+) human peripheral blood 
lymphocytes (PBL) intraperitoneally into immunodeficient (SCID) mice. Human cells 
showed T cell phenotype dominance one week after cell-transfer, whereas one month later a 
shift towards B cell phenotype was evident according to immuno-histochemical and flow-
cytometric analyses. At this stage the intraperitoneal mass of human lymphocytes suggested a 
biologically malignant behaviour infiltrating the liver and the spleen of the host animal. 
Immunohistochemistry indicated proliferating human lymphatic cells expressing an EBV 
associated protein LMP-1 and showed characteristic patterns of invasion within the affected 
organs. LPD was eventually lethal to the host animals within 46-67 days. However, the 
microscopic appearance of experimental LPD was different from human hemopoetic 
malignancies: the basic structures of lymphatic organs were preserved and human T and B 
cells repopulated normally T and B dependent areas in mice. The phenotype of the 
proliferating cells was characteristic for mature human T- and B-lymphocytes. No dominant 
clone developed during in vitro cultures of the biologically invasive mass of cells removed 
from the tumour-bearing mice. The results of microscopic, immunological, and flow-
cytometric analyses suggested the uncontrolled proliferation of otherwise normal primary 
human lymphocytes in SCID mice. 
The original method for the induction of post-transplant LPD in SCID mice was 
modified to standardize the experimental technique so as to increase the efficiency of EBV-
driven B cell proliferation and to reduce unspecific factors. Subsequent in vivo EBV 
superinfection with a known EBV subtype (B95-8) was carried out after the intraperitoneal 
transfer of a reduced quantity of human PBL from various donors. All hosts developed LPD, 
despite the significantly reduced amount of transplanted PBL. This reduced cell load was 
unable to establish LPD-like disease insufficient utilizing the original protocol. The progress 
of the disease was lethal in a shorter and narrower period of time (41-43 days) compared to 
the original model.   
 RT-PCR experiments were performed with two sets of PCR primers amplifying 
specific parts of the EBNA6 sequence to prove the dominance of the EBV subtype used for 
superinfection as the factor responsible for the standardization of the protocol. One set of 
primers denoted as EBNA6/1 identified the active EBV strain isolated from the LPD to 
belong to type ‘A’ EBV, just like the strain B95-8 used for superinfection. Another set of 
primers denoted as EBNA6/2 identified the active EBV strain isolated from the LPD to be the 
same B95-8 EBV subtype within type ‘A’ as the one used for superinfection.  
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1.2 Introduction 
Epstein, Achong and Barr described the Epstein-Barr virus or EBV in 1964.1 EBV is 
the 4th member of the herpes virus family (gamma herpes-virus) which contains a large 
amount of genetic information encoded in double stranded DNA (85 genes and over 172 kbp). 
EBV is a rather ubiquitous infective agent, over 90% of the human population is seropositive 
in the western world.2 The virus has a biphasic life-cycle: following extensive replication of 
the early lytic cycle, the EBV genome resides in the memory B cell compartment of the hosts. 
The early phase is related with the increased activity of a set EBV genes; while during the 
latent phase EBV gene activity is restricted to latency programs. The causal aetiology of EBV 
has been proven in numerous diseases such as infectious mononucleosis, Burkitt’s lymphoma, 
Hodgkin’s disease, nasopharyngeal carcinoma, gastric carcinoma and post-transplantation 
lymphoproliferative disease (LPD). (For a summary of some EBV-induced signal 
transduction pathways see Figure 1).  
Figure 1. Summary of some EBV-induced signal transduction pathways. 
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LPD may develop in EBV seropositive immunodeficient patients. These immune-
deficiencies by origin can be ‘natural’ (e.g. in AIDS, Duncan’s disease), or ‘artificial’ (as a 
result of chronic immunosuppressive treatment e.g. in post-transplantation medication). 
Among transplanted patients the occurrence of LPD is approximately 1%.3 Since chronic 
immunosuppression is becoming the part of everyday medicine the occurrence of LPD is 
likely to grow in the future. EBV subtypes differ in their ability to create LPD: ‘type A’ EBV 
is more potent than ‘type B’ EBV.2  ‘Type A’ LPD in younger patients has symptoms similar 
to infectious mononucleosis, infiltrating organs including the transplanted graft as well as the 
lymph nodes, bone marrow, liver, gastrointestinal tract, lungs, heart, nasal pharynx, thyroid 
glands and the central nervous system. ‘Type B’ LPD develops in senior patients in the form 
of solid tumors within the central nervous system and in the liver or elsewhere in the 
abdomen.4, 5 Ceasing immunosuppression usually heals LPD, but may simultaneously trigger 
graft rejection or the progression of other primary diseases. Different animal models are 
available for experimental LPD, but the induction of xenogeneic lymphoid chimeras in 
genetically immunodeficient mice shows most resemblance with human LPD.  
The C.B.17 scid/scid mice were first described in 1983. These mice have a 
spontaneous point mutation resulting a special defect of V(D)J recombinase system.2 As 
functional lymphocytes do not develop, these animals lack specific immune reactions and can 
easily host xenogeneic tissues. There are several methods to create chimeras by repopulating 
SCID mice with human lymphoid cells.6 One involves the transfer human PBL into mature 
SCID mice generally via an intraperitoneal injection thus creating what is called ‘hu-(PBL)-
SCID’. Although this method provides only a transient chimera condition for about six 
months, it is convenient and usually stable for a period long enough to examine some human 
diseases in vivo.7, 8, 9, 10 We refer to the above protocol as the original protocol. This method is 
still relevant, however it possesses some disadvantages: usually the amount of human PBL 
necessary for successful chimerism is rather high, around 5x107 cells per mouse per 
inoculation. In addition, different human blood donors most likely harbour EBV strains of 
various transforming capacities. These factors result irregular and highly unpredictable 
chimera-development and survival of host mice.11, 12, 13 
 The viral EBNA6 DNA sequence is highly diverse among different subtypes of EBV. 
Some features of the EBNA6 sequence are still subjects of debate. The very same fragments 
appear to be necessary for successful viral activity and to encode viral proteins that efficiently 
elicit immune responses. It is intriguing to have tandem repeats in a DNA sequence that 
encodes such an important yet immunogenic protein sequence. A primer pair referred to as 
EBNA6/2 partially overlaps one such tandem sequence. RT-PCR with these primers 
differentiated between subtypes of type ‘A’ EBV and identify dominant active EBV strains in 
tissue samples of the chimeras.14, 15
 
1.3 Materials and methods 
 
1.3.1 Animals 
An ethic committee has approved all experiments involving live animals and all 
necessary guidelines concerning the treatment of animals were observed. C.B.17 scid/scid 
homozygous mice were kept inbred in the animal facility at the Faculty of Medicine, 
University of Pécs, under specific pathogen free conditions. During experiments the animals 
were kept in a laminar cabinet in the Department of Immunology and Biotechnology. 
Ciprofloxacin (Ciprobay, Bayer) containing water was administered per os as antibiotic 
prophylaxis. 
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1.3.2 Cell lines 
 The B95-8 cell line harboring type ‘A’ EBV and the AG876 cell line containing type 
‘B’ EBV, both secreting complete infectious Epstein-Barr virions were cultured in DMEM 
containing 20% FCS for fourteen days in the Regional Laboratory of Virology, Baranya 
County Institute of State Public Health Service, Pécs, Hungary.  
 
1.3.3 Transplantation of human PBL 
Following the approval of the appropriate ethic committee and along with the 
informed consent of six different human blood donors, buffy-coats were prepared from their 
blood donations as sources of human PBL. According to attached qualifications mostly EBV+  
buffy-coats were used except for donor No.3, who was used as negative control. A suspension 
enriched in lymphocytes was obtained by density-gradient centrifugation (20°C, 20 minutes, 
2000/min.) over Ficoll solution (ρ=1.077 g/cm3). Cells were counted in Burker-chamber after 
staining with the tripane-blue cell-exclusion dye. The viability of PBL was higher than 90% in 
all cases. Intraperitoneal cell transfer was achieved with 1-6x107 cells per mouse per 
inoculation, depending on the protocol used (3-6x107 cells per inoculation following the 
original protocol and 1-2x107 cells per inoculation following the modified protocol). 
Altogether sixteen hu-PBL-SCID xenogeneic chimeras were created  
 
1.3.4 In vivo superinfection 
Three of the sixteen chimeras created altogether by the original and modified protocols 
were subjected to the in vivo superinfection protocol described below (Tables 1-2). The 
supernatant of the B95-8 cell line was centrifuged (20°C, 5 minutes, 1000/min) then filtered 
through 0.22 µm Whatman GF/C filter in order to eliminate cells and cellular debris. Ten days 
after intraperitoneal PBL transfer 1.5 ml purified supernatant was injected intraperitoneally 
into the host animals. The other three chimeras were not subjected to in vivo superinfection. 
An extra SCID mouse was control treated, EBV positive B95-8 supernatant was given 
without former PBL transfer.  
 
1.3.5 Antibodies 
The following anti-human monoclonal antibodies were used: anti- CD3, CD4, CD5, 
CD8, CD10, CD19, CD20, CD23, CD45, κ light chain, λ light chain, (all of them from 
DAKO, Denmark). Anti-mouse CD45 (IBL-5/25, developed in our laboratory), a-LMP 1and 
MIB-1 (both from DAKO, Denmark) antibodies were also used. 
 
1.3.6 Immunohistochemistry 
Histological examinations were performed on the intraperitoneal lymphoid mass and 
organs infiltrated by LPD (liver, spleen) from mice bearing clinical signs of malignant 
disease. Cryostat sections of frozen organs were fixed in acetone for 5 minutes then left to air-
dry for 2 minutes. Further reactions were performed in a humid chamber. After rehydration 
with PBS the inhibition of endogenous peroxidase activity was performed by using phenyl-
hydrasine-hydrochloride (1mg/ml) for 20 minutes. Non-specific binding sites were saturated 
by 5% BSA. Each antibody was incubated for 45 minutes followed by HRPO-conjugated 
anti-mouse IgG. The colour reaction was developed in Na-acetate buffer containing H2O2 and 
3-amino-9-ethyl carbasol (AEC). After 15 minutes colour development was stopped by PBS 
solution. Hematoxilin counter staining was used. Classical hematoxilin-eosin staining was 
also made from all the samples for microscopic classification of the pathologic events. 
Normal human lymphoid tissues and monoclonal antibodies with irrelevant specificity were 
used as positive and negative controls, respectively. 
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1.3.7 Flow cytometric analysis 
FACS phenotype analysis was performed on cells forming the intraperitoneal mass 
within LPD bearing mice and on cells cultured later on in vitro. Vortex-homogenization of the 
intraperitoneal mass of cells yielded a cell-suspension in PBS solution. Cells were incubated 
with FITC (fluorescein-isothyocianat) or PE (phycoerythrin) labelled antibodies for 30 
minutes on ice. Measurements were validated by carefully selected positive and negative 
controls. FACSCalibur type (Becton Dickinson, USA) flow-cytometer, and the CellQuest 
software (Becton Dickinson, USA) were used for analysis. 
 
1.3.8 In vitro cultures 
Following sterile biopsy from the infiltrated murine organs i.e. liver, spleen and from 
the peritoneal lymphoid mass, cells were mechanically dispersed and in vitro cultures were 
maintained in DMEM medium containing 10% FCS in a thermostat (Forma Scientific, USA) 
(37°C, 5% CO2 and saturated humidity) for a period of 6 weeks before cultures exhausted. 
 
1.3.9 Nucleic acid isolation 
 DNA of the B95-8 and AG876 cell lines was isolated by the GenElute Mammalian 
Genomic DNA Kit (Sigma). DNA sample isolated from the Akata cell line was a kind gift of 
János Minarovits M.D. Ph.D. (National Centre of Epidemiology, Budapest, Hungary). RNA 
was isolated from the peritoneal lymphoid mass using the GenElute Total RNA Kit (Sigma).  
 
1.3.10 Primers 
 The EBNA6/1 and EBNA6/2 primer pairs were synthesised by IDT (Integrated DNA 
Technologies, Inc.) and Sigma-Genosys Ltd, respectively. These primers cannot differentiate 
between DNA and cDNA as no introns exist within the amplified sequences. Therefore we 
performed DNase treatment. The used two pairs of primers both bind and amplify sequences 
of the EBNA6 gene. The EBNA6/1 pair helps to differentiate type ‘A’ and type ‘B’ EBV, 
while the EBNA6/2 pair surrounds a 39 bp tandem repeat sequence allowing the identification 
of various type ‘A’ EBV subtypes.16, 17, 18, 19 Details of the primers used are summarized in 
Table 3. 
 
1.3.11 DNase treatment, reverse transcription and polymerase chain reaction, 
visualization 
 DNase treatment of the RNA sample was carried out to eliminate DNA contamination, 
preventing false positive PCR results. Prior to reverse transcription and polymerase chain 
reaction the DNase enzyme was heat-inactivated to prevent decreased PCR sensitivity. 
Control reactions using RNA samples after DNase treatment but prior to cDNA synthesis 
were included in each set of PCR. For the above described procedures the DNase I. Kit 
(Sigma) was used.  
 Reverse transcription was performed starting from 1 µg of RNA sample and using 
random hexamer primers and the M-MLV enzyme according to the vendor’s instructions. All 
reagents used for reverse transcription were part of the SuperScript First Strand Synthesis 
system for RT-PCR (Gibco). Following reverse transcription 1µl of cDNA was further used 
as sample for polymerase chain reaction. All PCR reagents came with the AdvanTaq kit 
(Clontech) and we performed reactions as recommended in the kit manual. EBNA6/1 and 
EBNA6/2 PCR products required 45 in a PCR Sprint device (Hybaid). For high specificity at 
maintained sensitivity we performed ‘touchdown’ for the first 5 annealing and `time-
increment` for the last 10 elongation stages. Details are summarized in Table 4. 
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 The PCR products were run in 2% agarose gels containing ethydium-bromide. Both 
analogue and digital pictures were taken and analysed with the Scion Image software. 
 
1.4 Results 
 
1.4.1 Stages of LPD development following the original protocol 
Using the original protocol we created 10 hu-PBL-SCID xenogeneic chimeras with 
PBL from three different human blood donors (Table 1). LPD developed from the PBL of 
two donors. In the case of the third donor no LPD occurred since this control person was EBV 
seronegative. One week after cell transfer at the site of inoculation T-lymphocytes still 
represented the majority of human cells as FACS analysis showed the dominance of CD3+ 
cells compared to CD19+ cells (Figure 3A) isolated from the peritoneal mass, similar to 
human peripheral blood lymphocytes under normal conditions. 
The first sign of the developing LPD was the occurrence of a loosely structured tissue-
like mass of cells in the peritoneal cavity, in our case it was located adjacent to the portal 
region of the liver. The cells prepared from the peritoneal ‘tumour-like’ mass displayed 
human CD45+ according to flow cytometry (Figures 3B-3C). At this stage of the disease B 
cells began to proliferate and formed a dominant subpopulation. Among B cells some were 
CD23+ activated B cells. The T cell subpopulation was in minority by this time (Figures 3D-
3G). Immunohistochemistry revealed further details. The proliferative capacity of cells that 
formed the intraperitoneal mass could be demonstrated by their MIB-1 staining; such cells 
were scattered in a diffuse pattern indicating multifocal increased growth-rate (Figure 4A). 
The majority of tumour forming cells was κ light chain positive, that were polyclonal 
(Figures 4C-4D). The presence of EBV was confirmed by the expression of LMP-1 (latent 
membrane protein type 1) in a fraction of human B cells (Figure 4B). 
Dissemination of the human lymphoid cells occurred during the next stage of LPD. In 
addition to the mass of proliferating lymphoid cells located at the hilus of the liver and the 
spleen macroscopic haemorrhage-infarcts appeared on the surface of the liver. Tissue samples 
of the liver and the spleen were analyzed by histology. Proliferating lymphocytes infiltrating 
the tissue were easily distinguished from the hepatocellular background following 
hematoxilin-eosin staining by microscopy examination (Figure 4E). Immunohistochemistry 
revealed characteristic localization of human lymphocyte subsets in the spleen. The CD3+ T 
cells preferred the periarteriolar lymphatic sheaths (PALS) in the spleen, while the CD20+ B 
cells clustered into follicles (Figures 4F-4H) similar to physiological distribution. LPD was 
lethal to mice in 46-67 days, the moribund state was accompanied by palpable abdominal 
tumour, weakness, hypokinesis and ruffled fur (Table 1 and Figure 2).  
 
1.4.2 In vitro cultures of tumour cells 
Cells removed from the host animals could be cultured in vitro for approx. 6 weeks. At 
small magnification colonies formed large spherical groups due to increased growth rate and 
cells sticking together following division. Based on flow-cytometry the CD19+ tumour cells 
were CD5- and CD10- indicating that they were B cells, but not B1 or centroblast cells 
(Figures 3H-3I). No dominant clone developed, though light chain profile still favoured the κ 
positive population compared to the λ positive population (Figure 3J). 
 
1.4.3 Inducing LPD by the modified protocol 
Using the modified protocol we created altogether 6 chimeras with PBL from three 
different human blood donors (Table 2). In each pair of mice one was treated with subsequent 
in vivo superinfection: an i.p. injection of 1.5 ml B95-8 supernatant. A SCID mouse injected 
with 1.5 ml of B95-8 supernatant without prior cell transfer served as negative control. Note  
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No. of 
mouse 
No. of 
donor 
PBL 
injection 
PBL per 
mouse 
LPD 
emergence 
survival 
(days) 
1. 1. Yes 4x107 * * 
2. 1. Yes 5x107 Yes 55 
3. 2. Yes 4x107 * * 
4. 2. Yes 5x107 Yes 46 
5. 2. Yes 6x107 Yes 67 
6. 3. Yes 4x107 * * 
7. 3. Yes 5x107 * * 
8. 3. Yes 3x107 No >122 
9. 3. Yes 5x107 No >122 
10. 3. Yes 6x107 No >122 
Table 1. Summary of original chimera creation protocol. Asterisks (*) show animals sacrificed for 
FACS measures. Donor No. 3 was EBV seronegative. 
 
 
No. of 
mouse 
No. of 
donor 
PBL 
injection 
EBV 
injection 
LPD 
emergence 
survival 
(days) 
11. 4. Yes No No >74 
12. 4. Yes Yes Yes 41 
13. 5. Yes No No >74 
14. 5. Yes Yes Yes 42 
15. 6. Yes No No >74 
16. 6. Yes Yes Yes 43 
17. --- No Yes No >74 
Table 2. Summary of modified chimera creation protocol. All mice subjected to PBL injection received 
1-2x107 cells per mouse per inoculation. Survival was followed for 74 days. 
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Figure 2. Differences between the protocols in the  average of survival and the standard 
deviation of survival 
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 Figure 3. Characterization of the hu-SCID chimera system by flow-cytometry. 
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Figure 3A. Site of inoculation 
prior to LPD development. 
Figure 3B. Species origin of 
the periportal mass of cells. 
Figure 3C. Species origin of 
the periportal mass of cells. 
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Figure 3D. Phenotype of 
the periportal mass of cells. 
Figure 3E. Phenotype of  the 
peritoneal mass of cells. 
Figure 3F. Phenotype of the 
peritoneal mass of cells. 
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Figure 3G. Phenotype of 
periportal mass of cells. 
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Figure 3J. Clonality of 
in vitro cultured cells. 
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Figure 3H. Phenotype of  
in vitro cultured cells. 
Figure 3I. Phenotype of 
in vitro cultured cells. 
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Figure 3K. Phenotype of 
ex vivo peritoneal LPD. 
Figure 3L. Pheno
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that neither the transfer of a smaller amount of PBL alone from EBV seropositive donors nor 
the in vivo administration of B95-8 supernatant on its own caused the emergence of LPD. In 
chimeras that received subsequent in vivo superinfection LPD developed and proved to be 
lethal in 41-43 days (Table 2 and Figure 2). At the autopsy of affected mice an 
intraperitoneal mass of cells in the ascitic fluid and enlarged, unusually pale liver and spleen 
were observed. Flow-cytometric analysis of the intraperitoneal mass of cells showed mainly 
human CD45+ phenotype and the dominance of CD19+ B cells compared to CD3+ T cells 
(Figures 3K-3L). The double negative population contained murine cells (figures not shown). 
In vitro cultures of cells removed from the peritoneal cavity of moribund LPD hosts showed 
high capacity for proliferation for over a month before cell division halted. At small 
magnification colonies formed large spherical groups of cells adhering to each other 
following division. 
 Six chimeras were created following our modified protocol (Table 2). Three mice 
received PBL transfer alone and three others were also subjected to in vivo superinfection ten 
days after PBL inoculation. When the PBL transfer was not followed by in vivo EBV 
superinfection all animals survived beyond 74 days (time of follow-up), due to the insufficient 
amount of human cells for LPD induction. However, all three mice died in 41-43 days if PBL 
inoculation was followed by in vivo EBV superinfection. In our earlier experiments following 
the original protocol of chimera creation, survival figures varied between 46-67 days with an 
average of 56 days (Tables 1-2 and Figure 2).  
 
1.4.4 PCR differentiation of EBV types and subtypes 
 First we tested our EBNA6/1 PCR system for its ability to distinguish the two major 
types of EBV. Figure 5 demonstrates that by using the EBNA6/1 primer pair our PCR system 
clearly differentiates type ‘A’ and type ‘B’ EBV due to the size difference of amplicons 
characteristic for the two major types of EBV. Figure 6 illustrates that if RT-PCR is 
performed with the DNase treated RNA sample extracted from the peritoneal lymphoid mass 
it produces only one amplicon, the one that is characteristic of type ‘A’ EBV. 
 The EBNA6/2 primer pair was also tested in our PCR system before application. As 
shown on Figure 7 the EBNA6/2 system can differentiate between different subtypes within 
type ‘A’ EBV. Figure 8 shows that if RT-PCR is performed with the DNase treated RNA 
sample isolated from the peritoneal lymphoid mass only one amplicon is produced, that is 
characteristic of subtype B95-8 of type ‘A’ EBV based on the length of the amplicon. In all 
PCR experiments the lane for genomic DNA contamination verifies the efficiency of DNase 
treatment and the purity of the resulting RNA sample. Software assisted image analysis 
confirms the absence of contaminating PCR products as seen attached below the PCR images. 
(Tables 3-4 summarize the specifications of the primers and PCR conditions used.) 
 
1.5 Discussion 
 There is always uncertainty in creating a hu-PBL-SCID xenogeneic chimera model. 
The survival of the graft depends on many factors that are not all clearly understood or can 
not be interfered properly.20 For example: graft versus host reaction can drastically influence 
the biological response of the recipient. The likelihood of graft acceptance can be raised with 
the increase of input cell quantity and careful protocols that spare cell functions. In the 
original protocol for creating hu-PBL-SCID models the minimally required amount of cells is 
approx. 5x107 cells per inoculation, as smaller quantities usually fail to successfully 
repopulate the host.7 In vitro activation of human cells prior to transfer may also be helpful. 
PBL donors can be divided into at least two groups based on the incidence of LPD. The 
ability of donors to create LPD in SCID mice is constant with time and it is characteristic to 
donors. Approx. 40% of donors belong to the high incidence group and 60% to the low- 
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 Figure 4. Characterization of the hu-SCID chimera system by histology. 
  100 µm
 
 
 
Figure 4A. Intraperitoneal mass of cells, 
MIB-1 immunohistology, 40x 
Figure 4B. Intraperitoneal mass of cells, 
a-LMP-1 immunohistology, 40x 
Figure 4C. Intraperitoneal mass of cells, 
a-κ light chain immunohistology, 40x 
Figure 4D. Intraperitoneal mass of cells, 
a-λ light chain immunohistology, 40x 
Figure 4F. Infiltration of the spleen, 
a-CD20 immunohistology, 100x 
  
  200 µm
  
   40 µm 
Figure 4E. Infiltration of the liver, 
hematoxilin-eosin staining, 40x 
Figure 4G. Infiltration of the spleen,
a-CD3 immunohistology, 20x 
Figure 4H. Infiltration of the spleen,
a-CD20 immunohistology, 20x 
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Figure 5. PCR differentiating between type ‘A’ 
and type ‘B’ EBV using the EBNA6/1 primer pair. 
Above: PCR picture. Below: image analysis. The 
lanes are: (left to right) DNA size marker, 
negative control reaction, sample from B95-8 
EBV (type ‘A’), sample from AG876 EBV (type 
‘B’). 
 
 
Figure 6. RT-PCR identifying the type of EBV in 
the sample from a hu-(PBL)-SCID chimera with 
LPD using the EBNA6/1 primer pair. Above: RT-
PCR picture. Below: image analysis. The lanes 
are: (left to right) DNA size marker, negative 
control reaction, sample from B95-8 EBV (type 
‘A’) used as positive control, genomic control 
reaction, LPD sample from a chimera. 
 
 
     marker         - CTRL         B95-8          Akata                      marker      - CTRL     + CTRL   gen. CTRL    LPD 
 
 
Figure 8. RT-PCR identifying the subtype of 
EBV in the sample from a hu-(PBL)-SCID 
chimera with LPD using the EBNA6/2 primer 
pair. Above: RT-PCR picture. Below: image 
analysis. The lanes are: (left to right) DNA size 
marker, negative control reaction, sample from 
B95-8 EBV (type ‘A’) used as positive control, 
genomic control reaction, LPD sample from a 
chimera. 
 
Figure 7. PCR differentiating between 
subtypes of type ‘A’ EBV using the EBNA6/2 
primer pair. Above: PCR picture. Below: image 
analysis. The lanes are: (left to right) DNA size 
marker, negative control reaction, sample from 
subtype B95-8 (type ‘A’ EBV), sample from 
subtype Akata (also type ‘A’ EBV). 
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intermediate incidence group. The incidence of LPD in the two groups shows no direct 
relation with the concentration of latently infected B cells in PBL. The frequency of latently 
infected cells among B-lymphocytes in the peripheral blood is individual and varies 
considerably. In a population of healthy carriers this is between 5-500x10-7 with a mean of 
50x10-7 and this value is characteristic to each donor. The low concentration of latently 
infected cells is due to the fact that it concerns only a fraction of memory B cells and can also 
explain the relatively high number of cells required for successful LPD formation in the 
chimeras. Immunosuppression during human allograft transplantation protocols causes an 
average 40-50 fold increase of latently infected B cells in the peripheral blood of patients. 
Their increased numbers may be due to the prolonged survival or increased production of 
precursors that are under direct cytotoxic control.21 The prevalence of CD8+ cells within the 
graft is also variable, hence inadequate cytotoxic immune-surveillance may also play a part in 
lymphoproliferation. Besides the mentioned uncertainties of creating chimera models, the 
exact time-span necessary for LPD emergence can not be precisely forecasted. In case of an 
EBV+ PBL donor the chances of developing LPD within 60-110 days is about 80-100%.  
The original method for inducing post-transplantation LPD in SCID mice was 
modified during our experiments to standardize and increase the efficiency of B cell tumour 
occurrence with the reduction of unspecific factors. We transferred a smaller quantity of 
human PBL compared to the original protocol and then administered EBV from the B95-8 
cell line as subsequent in vivo superinfection. These alterations apparently circumvented some 
points of variation. The well-known human LPD developed in the animals, but a fraction of 
the formerly used amount of cells of EBV seropositive donors was sufficient to develop the 
disease in a slightly shorter and in a narrower time-span regardless of further donor 
characteristics. Following the modified protocol the intraperitoneal transfer of 1-2x107 
lymphocytes was sufficient to create LPD compared to 5x107 with the original protocol, 
average survival decreased from 56 to 42 days and more importantly standard deviation of 
survival fell from 10.5 days to 1 day. 
 Based on serology data, the donors of human lymphocytes were all EBV positive . 
However, the type or subtype of pre-existing EBV in donors was not identified prior to PBL 
transfer. There are many subtypes of EBV present in human population. By the EBNA6/2 
system alone, 13 cell lines harbouring different type ‘A’ subtypes of EBV were tested and 
described in literature.16, 17 It is most unlikely that originally all three buffy-coat donors shared 
the same subtype of EBV during our experiments. Yet, based on RT-PCR, in all three 
chimeras the only active EBV strain was the B95-8 subtype used for superinfection. Also 
survival figures of the chimeras following the modified protocol were rather uniform. The 
dominance of subtype B95-8 compared to viral strains pre-existent in B-lymphocytes is 
supported by repeated RT-PCR experiments. Apparently the viral strain used for 
superinfection had an advantage of mutliplication compared to the EBV strains acquired 
previously by the B-lymphocytes. We believe that much of this advantage comes from the 
that the hu-(PBL)-SCID chimeras provide an initially constitutive, sustained immune-
compromised environment and in vivo superinfection occurred under such circumstances. It 
seems that if EBV superinfection takes place parallel to immuno-suppression, the EBV 
subtype used for superinfection has an advantage of replication compared to EBV subtypes 
acquired earlier, present in a quiescent form within the B-lymphocytes. In turn this leads to a 
faster lymphoproliferation and a consequently more malignant biological behaviour ultimately 
resulting PBL donor independent survival figures of chimeras created following our modified 
protocol. 
 The situation described above closely resembles the immunosuppressed state found in 
many post-transplant patients due to their immunosuppressive medication. EBV 
superinfection occurring in post-transplant patients receiving immunosuppressive therapy can 
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lead to PT-LPD cases that develop and propagate rapidly and share poor prognosis if 
unnoticed in time.18, 22, 23, 24, 25 It is therefore strongly recommended in all chronically 
immunosuppressed patients that, in addition to regularly measuring total EBV load in the 
peripheral blood by i.e. real-time quantitative PCR, recently acquired EBV strains should also 
be identified. This preventive follow-up may call attention to imminent cases of PT-LPD that 
are hard to treat if not recognized in time.26, 27, 28, 29, 30  
  
 
 EBNA6/1 pair EBNA6/2 pair 
sequences  
sense 
anti-sense 
5’-AGA AGG GGA GCG TGT 
GTT GT-3’ 
 
5’-GGC TCG TTT TTG ACG TCG 
GC-3’ 
5’-GAA ATG CGG GCT GGT CGT 
GAA-3’ 
 
5’-CTT GTT GGA ATG GGG CGT 
ATG-3’ 
amplicon 
size 
153 bp (type ‘A’) 
246 bp (type ‘B’) 
724 bp (subtype B95-8) 
724-1124 bp (known subtypes) 
co-ordinates 
in EBV 
genome 
 
99939-100091 
 
100395-101119 
Table 3. Details of the primer set utilized. 
 
 
 
 EBNA6/1 EBNA6/2 
primary denaturation 95°C, 3min. 95°C, 3min. 
cycles with  
`touchdown`  
(5 cycles) 
95°C, 30sec. 
70°C, 30sec.↓2°C/cycle 
72°C, 70sec. 
95°C, 30sec. 
60°C, 30sec.↓1°C/cycle 
72°C, 20sec. 
main cycles 
(30 cycles) 
 
95°C, 30sec. 
60°C, 30sec. 
72°C, 70sec. 
95°C, 30sec. 
55°C, 30sec. 
72°C, 20sec. 
cycles with  
time increment 
(10 cycles) 
95°C, 30sec. 
60°C, 30sec. 
72°C, 70sec.↑2sec./cycle 
95°C, 30sec. 
55°C, 30sec. 
72°C, 20sec.↑1sec./cycle 
final elongation 72°C, 5min. 72°C, 5min. 
Table 4. Details of PCR thermal cycles. 
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SECTION II. 
 
Establishment of a human primary B cell monoculture system 
for efficient lentiviral transduction and gene function assay 
 
2.1 Summary 
 
 Recently, using HIV-1-derived lentivectors, we have obtained efficient transduction of 
primary human B lymphocytes co-cultured with murine EL-4 B5 thymoma cells. However, 
efficient lentiviral transduction of human primary B cells has so far only been feasible in such 
co-culture assays, not in mono-cultures of B cells. We have now found that transduction of B 
cells in a mono-culture system using CpG DNA was comparable to that in the EL-4 B5 co-
culture system.  
 Following the stimulation of human primary B cells by CpG motifs (see Figure 9 as 
the summary of TLR-mediated signal transduction pathways), anti-Ig and the human 
recombinant cytokines IL2 and IL10 a monocistronic vector with a CMV promoter gave 32 ± 
4.7% GFP+ human primary B cells cells, which value for transduction efficiency is 
considered as robust, given the natural variety of human blood-donors. The EF1α promoter 
has also been tested, but performed inferior as seen earlier in our experiments and in 
accordance with previous reports. Also we have selected and transduced transgenes other than 
GFP as ‘proof-of-principle’ for the method. We have utilized both a secreted and an 
intracellular transgene to prove functionality of the expressed proteins following lentiviral 
transduction. In the same B/CpG system as above a bicistronic vector under the control of the 
CMV promoter, encoding either IL-4 or vFLIP as the first cistron and than GFP as the second 
cistron, gave 14.2 ± 2.1% GFP+ cells. The EF1α promoter showed even more impaired 
capabilities in these bicistronic than monocistronic vectors.  
 We measured transgenic IL-4 secretion to be 1.3±0.2ng for 105 B cells in 24 hours 
using carefully selected experimental conditions and controls. In secondary culture systems 
transgenic IL-4 proved to be fully functional on B cells (promoting IgE switch in the EL4 B5 
co-culture system and increased proliferation in the CD40L system, data not shown). 
Following transduction with a bicistronic vector encoding the viral FLIP molecule, vFLIP was 
detectable by both flow-cytometry and Western blot in GFP+, but not in GFP- B cells. When 
functional assays were employed to measure vFLIP-mediated rescue from FasL-triggered 
apoptosis, GFP+ (thus vFLIP+) cells were enriched among viable cells from 4% to 16% and 
22% by FasL in a dose dependent manner (0 ng/ml, 100 ng/ml and 200 ng/ml, respectively). 
(Initial transduction efficiencies were kept low by utilizing low viral MOI to keep headroom 
for the anticipated enrichment of protected cells). In another assay following sort-enrichment 
of GFP+ (thus vFLIP+) cells 57% of the sorted GFP+ B cells were rescued from FasL-
induced cell death as proved by their increased thymidine-incorporation   
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 Figure 9. Simplified summary of TLR-mediated signal transduction pathways. 
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2.2 Introduction 
 
 The human immune-deficiency virus-1 (HIV-1) is a human pathogen, a retrovirus that 
belongs to the lentivirus family of RNA viruses. With the aid of modern biotechnology HIV-1 
based artificial lentiviral vectors have been constructed from wild type pathogens. Vectors 
created following the removal of wild type genetic elements necessary for virulence and 
replication may be used with standard P2 laboratory infrastructure. For safety and practical 
considerations, the remaining fraction of the wild type HIV-1 genome (approx. 15%) has 
further been split into three parts encoded by separate plasmids (Figure 10). One encodes the 
envelope protein. Another encodes the structural enzymes required for the packaging of 
lentivectors (gag and pol). The third so-called transfer plasmid encodes the transgene of 
interest embedded in a modified lentiviral LTR (long terminal repeat) frame. This LTR 
sequence allows only for the integration of the transgene of interest, but none of the other 
lentiviral genes. Beyond safety precautions, splitting the information required for efficient 
lentiviral vector preparation into three plasmids is also very practical: modification can easily 
be made to the envelope, packaging or transfer plasmids separately. These modifications 
provide a safe, yet efficient and flexible vector that enables the stable genetic modification of 
many primary cells and cell-lines.  
 High efficiency: In late second generation lentiviral vectors the cPPT sequence has 
been reinserted from the wild type virus as this small sequence facilitates nuclear entry of 
viral DNA, increasing biological titers with one order of magnitude.31 The transfer plasmids 
used for the experiments contained the WPRE/WHV sequence that stabilizes transgenic 
mRNA prolonging its half-life and thus increases transgene expression level.32 If the gp120 
wild type envelope protein is substituted by VSV-G (vesicular stomatitis virus G-protein), 
target cell tropism broadens significantly so the vectors can efficiently transduce virtually any 
mammalian cell.33 These pseudotyped vectors also gain increased physical resistance that 
allows for their concentration by ultracentrifugation. For the expression of two separate (non-
fused) transgenic proteins under the control of a common promoter bicistronic vector 
constructs were used (i.e. IL-4 and GFP or vFLIP and GFP). In these cases the 
encephalomyocarditis virus IRES sequence was inserted between the two transgene 
sequences.34 This way, although the two transgenes share a common mRNA following 
transcription (resulting direct proportion relation), the two sequences are translated into two 
separate proteins that are not fused, avoiding possible functional interference. So the 
transduced cells express GFP and also secrete IL-4 or express intracellular vFLIP, depending 
on vector construct. It is common to place GFP after IRES, since it is readily detectible. Yet 
there is often a decrease of GFP+ cells in the case of utilizing bicistronic vectors compared to 
monocistronic vectors (encoding GFP alone).  
 Safety: The above LTR sequence contains a SIN (self-inactivating) mutation that takes 
effect upon integration, further increasing safety and decreasing expression in non-specific 
cells and tissues.35 Right on the external margins of the LTR sequences LoxP sites have also 
been introduced.36 Following integration the LoxP sites enable the cre enzyme to excise the 
entire transgenic sequence leaving behind nothing but a viral scar. This option serves double 
function. Assuring safety is one of its functions: if the presence of the transgene is no longer 
desired than it may be eliminated by the addition of cre enzyme of the affected cells. On the 
other hand, this way the same cells that were formerly used for the experiments may later be 
used as their very own negative controls following treatment with cre. 
 Optimization of methods for gene delivery into primary human cells is important for 
research on gene functions and development of gene therapies.37 Gene transfer into primary 
human B lymphocytes has been notoriously difficult. Recently we have obtained efficient 
transduction38 with HIV-1-derived lentiviral vectors as follows.39 Like for T cells, activation  
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 Figure 10. Vector maps of the three 
plasmids required for the preparation 
of lentiviral vectors. At top left is the 
envelope constructs (pMD2.G) 
encoding the VSV-G envelope 
protein; at bottom left is the 
packaging construct the gag end pol 
genes; top right shows a transfer 
plasmid (this the a monocistronic 
construct EF1α:GFP). 
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of the B cells was necessary.40, 41 In B cells co-cultured with irradiated murine EL-4 B5 
thymoma cells and human cytokines, HIV-1 based lentiviral vectors with the human 
cytomegalovirus (CMV) or elongation factor-1α (EF-1α) internal promoter provided efficient 
transduction efficiencies.38 On the other hand, T-B co-culture is cumbersome, and a 
disadvantage for various research applications is that the functions of the thymoma cells are 
not yet molecularly characterized. Isolated B cells activated by cross-linking of CD40 in the 
presence of various cytokines were very poorly transducible with HIV vectors.38, 42  
Therefore our aim was to find a mono-culture system for the efficient transduction with 
HIV vectors of isolated B cells activated by defined stimuli. The LPS receptor, Toll-like 
receptor-4 (TLR4), is absent on/in human B cells.43, 44 But TLR9, the receptor for immune-
stimulatory CpG DNA, is expressed by memory human B cells, and up-regulated on naive B 
cells by anti-immunoglobulin (Ig) antibody, which mimics an antigen signal.43, 44 We have 
found that monocistronic and bicistronic HIV-1-derived vectors ensure an efficient means of 
gene transfer in the CpG DNA-dependent B cell monoculture system that operates with 
defined stimuli of activation. 
  
2.3 Materials and methods 
 
2.3.1 HIV-1-derived vectors 
A second-generation packaging system and self-inactivating HIV-1 vectors with the LoxP site 
in the 3’ LTR were utilized.45, 46 The monocistronic vector with the EF-1α internal promoter 
(called vector EF1α-GFP in this study) was plasmid pWPTS-GFP. This plasmid carries, in 5’ 
to 3’ direction, the cPPT element, the intronless (‘short’) EF-1α promoter, the expression 
cassette, and the WPRE.47, 48 Vector CMV-GFP was made by replacing the promoter with the 
human CMV promoter between the ClaI and the BamHI restriction sites.49 In the bicistronic 
vectors, which were derived from the above vectors, the first cistron was the transgene of 
interest, between the BamHI and the SalI restriction sites, followed by the 
encephalomyocarditis virus IRES and GFP encoded downstream of the IRES.46 In the vectors 
EF1α-IL-4-GFP and CMV-IL-4-GFP the transgene was the complete human IL-4 cDNA 
sequence (a kind gift from Dr. J.-F. Gauchat, formerly at the Institut Pierre Fabre, St. Julien, 
France). In vector CMV-vFLIP-GFP the transgene was the FLAG-tagged viral FLIP of 
human molluscum contagiosum virus (open reading frame 159L), kindly provided by Dr. 
Margot Thome of the Department of Biochemistry, University of Lausanne.50 Virus particles 
pseudotyped with vesicular stomatitis virus G glycoprotein were produced, concentrated 100-
fold by ultracentrifugation, and titrated on HeLa cells by measurement of GFP+ cells by 
FACS to establish HeLa transducing units per milliliter (usually 0.5-2x108), as described.51 
Viral stocks were suspended in B cell culture medium and stored at -70°C. 
 
2.3.2 Cell cultures and transduction 
Approval for research on human cells was obtained from the Ethics Committee of the Geneva 
University Hospitals. Written consent was provided for all cell samples. B cells were isolated 
to more than 98% purity from buffy-coats of virus-screened blood donations obtained from 
the Geneva Transfusion Center using Ficoll–Hypaque centrifugation and anti-CD19 magnetic 
beads (Dynal). All B cell cultures were grown in RPMI 1640 medium supplemented with 
10% fetal calf serum, 2-mercaptoethanol, Hepes buffer, and antibiotics as described. 
 
2.3.3 CpG DNA system  
B cells (25,000 cells/200 µl culture; flat-bottom 96-well plates) were stimulated with CpG 
DNA (2.5 µg/ml), anti-Ig antibody (2 µg/ml), IL-2 (50 ng/ml), and IL-10 (10 ng/ml). CpG 
oligonucleotides of the published sequences C274, 2006, and C661 were obtained as complete 
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phosphorothioates synthesized to our order by Microsynth (Balgach, Switzerland). Anti-Ig 
was goat F(abV)2 anti-human IgA + IgG + IgM (H+L) (Jackson ImmunoResearch). The 
cytokines were from PeproTech. FACS sorting of CD27+/CD27- cells was done as described. 
52, 53
 
2.3.4 CD40L system  
B cells (50,000 cells/200 µl) were stimulated with a soluble oligomeric CD40L (300 ng/ml), 
IL-2 (50 ng/ml), and IL-10 (10 ng/ml) as described.52 When CD40L was added to the CpG 
DNA system or the EL-4 B5 system, its concentration was 300 ng/ml.  
 
2.3.5 EL-4 B5 system  
B cells (3,000 cells/200 µl) were stimulated with 50,000 irradiated EL-4 B5 murine thymoma 
cells and a mixture of human cytokines acting on the EL-4 B5 cells (IL-1β) or the B cells 
(TNF-α, IL-2, and IL-10), as described.51 To transduce B cell cultures at different time points, 
the big cell clusters, which formed in all culture systems, were dispersed by gentle pipetting 
(five times aspiration of the culture using 200µl tips). Virus particles were then added to the 
cultures in a volume of 2 to 4 µl, at the indicated MOI according to cell counts by microscope 
(B cells or B plus EL-4 B5 cells), without further manipulations or cell wash. We found that 
centrifugation of virus particles in new culture plates (spinoculation) with cell transfer did not 
give better results. 
 
2.3.6 Sorting and FACS analysis of transduced cells  
GFP+ cell populations were sorted on a FACStar sorter, and analyses of GFP+ cells were 
performed using CellQuest software (Becton–Dickinson), at the cytofluorometry laboratory of 
the Geneva Medical Center. Cells were pretreated with polyclonal mouse Ig before staining 
with phycoerythrin (PE)-coupled anti-CD19 and viable (7-amino-actinomycin-D low) cells 
were gated for analysis of GFP expression.51 For analysis of cytoplasmic IL-4, cells were 
cultured with brefeldin A (Sigma) 2.5 µg/m for 3 hours. For analysis of cytoplasmic IL-4 or 
viral FLIP, cells were treated with Cytofix/Cytoperm and Perm/Wash solutions, followed by 
AB+ serum, and then stained, respectively, with PE-coupled anti-IL-4 mAb (Pharmingen) or 
anti-FLAG-M2 mAb (Sigma), which we coupled to biotin, followed by PE-coupled 
streptavidin (Jackson ImmunoResearch). The isotype control was mouse IgG1. Apoptosis was 
assessed using the Annexin V–PE Apoptosis Detection Kit I (Becton–Dickinson). 
 
2.3.7 IL-4 secretion rate 
On day 2 or 3 after addition of viral particles, B cells cells were harvested and washed twice 
in culture medium in Eppendorf tubes, and viable, trypan blue-excluding cells were counted. 
The cells were re-cultured as before, and after 24 h soluble IL-4 was measured in culture 
supernatants by Quantikine Human IL-4 Immunoassay (R&D Systems). 
 
2.3.8 Real-time quantitative PCR 
The LightCycler system, High Pure PCR Template Preparation Kit, and LightCycler FastStart 
DNA MasterPLUS SYBR Green I kit (all from Roche) were utilized. PCR was performed in 
separate assays for genomic DNA, using intron-binding primers for β2-microglobulin (5’-
GGCACTGCTGAGATACTGAT-3’, reverse 5’-GCTAGGACAGCAGGACTTA-3’; 215-bp 
product) and for vector DNA, using GFP primers (5’-GGCAAGCTGACCCTGAAGTT-3’, 
5’-GCATGGCGGACTTGAAGAAGT-3’; 149-bp product); respective plasmid standards 
were utilized. 
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2.3.9 FasL assays 
The protective effect of vFLIP against apoptosis was assayed both by flow-cytometric and 
cell-proliferation assays (thymidine incorporation).  
Flow cytometry: B cells in the CpG system were transduced on day 2 by low quantities of 
lentiviruses (CMV:GFP or CMV:vFLIP-GFP) at MOI of 1. Some cultures were not 
transduced as control cultures. Then 3 days following transduction the cells were given 
different concentrations of FasL (0, 100 or 200 ng/ml) for 48 hours. Then on day 7 of the 
culture viable B cells in the gate of living cells (7AAD negative) were assayed for GFP 
expression by flow-cytometry.  
Cell-proliferation: Following transduction of B cells as above, GFP+ cells were sorted on day 
5, that is 3 days after exposure to vector and re-cultured (20,000 trypan blue-excluding 
cells/200 µl, triplicate cultures) in the CpG DNA system (without anti-Ig) in the presence of 
soluble oligomeric FasL (200 ng/ml) prepared as described.54 Thymidine incorporation was 
measured after 48 hours including the pulsing during the last 12 hours with 1 µCi (0.037 
MBq) [methyl-3H] thymidine (Amersham Pharmacia Biotech).52
 
 
2.3.10 Western blot for viral FLIP 
This was done with the ECL Western blotting analysis system (Amersham) using 0.45µm 
nitrocellulose membranes (Bio-Rad) and Biomax chemiluminescence films (Kodak). The 
antibodies were IgG1 mouse anti-FLAG-M2 mAb (Sigma) or polyclonal goat IgG anti-actin 
(Santa Cruz Biotechnologies) in conjunction with horseradish peroxidase-coupled anti-mouse 
or anti-goat antibodies, respectively (Santa Cruz Biotechnologies). 
 
2.4 Results and discussion 
 
2.4.1 B cell transduction in the CpG DNA system 
We found that peripheral blood B cells stimulated by CpG DNA, anti-Ig antibody, and the 
cytokines IL-2 and IL-10, according to Bernasconi et al., were efficiently transduced by HIV 
vectors. For monocistronic (GFP) and bicistronic (IL-4–GFP or vFLIP-GFP) vectors, the 
mean fluorescence intensity (MFI) of GFP+ B cells was always higher (2.5-fold or more) with 
the CMV than with the EF-1α internal promoter (Figure 11), confirming our previous 
findings with monocistronic vectors.51, 55 As expected, the percentages of GFP+ cells were 
lower with the bicistronic compared to the monocistronic vectors (3- or 2.3-fold by the mean, 
respectively, for the EF-1α or CMV promoter; for the CMV promoter, mean data are shown 
on Figure 12). 
 The CG-rich oligonucleotides C274 (21 bases) and 2006 (24 bases), which triggered 
optimal B cell proliferation in the study by Marshall et al., both allowed for efficient 
transduction, whereas oligonucleotide C661, with all CG inverted to GC, gave 20-fold lower 
proliferation and transduction.[16] Vectors had to be added to the B cell cultures on day 2 or 
later. At an of MOI 20 HeLa cell-transducing units per B cell the numbers of GFP+ cells were 
1.2-fold higher by the mean than at an MOI of 10, but at an MOI of 30 or higher the numbers 
progressively decreased.  
 
2.4.2 Comparison of different B cell culture systems 
Viable cell expansion in the CpG DNA system set up with total peripheral blood B cells was 
fivefold by the mean in 10 days. Individual B cells proliferate very heterogeneously in this 
system.[10] At least fivefold higher B cell expansion was obtained in the system using EL-4 
B5 murine thymoma cells as helper T cells.51, 56 But the percentages of transduced B cells 
among the viable cells analyzed on day 6 or 7 were very similar in both systems (Figure 12,  
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Figure 11. The MFI of GFP in B cells transduced with monocistronic or bicistronic HIV vectors was 
higher with the CMV than with the EF-1α internal promoter. Note the similar tendency of reduced GFP 
expression when bicistronic constructs were used. Virus particles for the indicated vectors were added 
to parallel cultures on day 3 at an MOI of 10 to B cells cultured in the CpG DNA system. FACS analysis 
was done on viable cells on day 6. 2-D plots show staining with PE-anti-CD19 mAb on the y axis 
(isotype controls gave <0.5% background). Percentages of GFP+ cells and MFI of these cells are 
indicated by upper and lower numbers, respectively, in the histograms.  
 
Figure 12. Differences in B cell transducibility by HIV vectors under various culture conditions. Vectors 
CMV:GFP or CMV:IL-4-GFP were added on day 3 (MOI of 10) to the CD40L system (CD40L), CpG DNA 
system (CpG), CpG DNA system in the presence of CD40L (CpG + CD40L), EL-4 B5 system (EL-4 B5), 
or EL-4 B5 system in the presence of CD40L (EL-4 B5 + CD40L). FACS analysis was done in viable 
cells on day 6 or 7. Shown are means ± 1 SEM for percentages of GFP+ B cells from nine independent 
experiments for each culture condition. Transduction in CpG versus CpG + CD40L, and in EL-4 B5 
versus EL-4 B5 + CD40L, was compared in parallel experiments. Significant, opposite effects of CD40L 
on transducibility were found with both vectors (**P < 0.001; *P < 0.05; by two-sided t test). 
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CpG and EL-4 B5; there were about 30 and 14% GFP+ cells, respectively, for vectors 
CMV:GFP and CMV:IL-4-GFP). Since activated B cells proliferated and outnumbered non-
proliferating cells, this means that proliferating B cells were similarly transduced in both 
systems. Various cell types, e.g., T cells, after some activation become transducible with 
lentivectors even if they do not divide.41, 42 So far this could not be studied with B cells, 
because - unlike for T cells - B cell populations could not be maintained in an activated, yet 
non-dividing state. 
 In agreement with our previous data, however, transducibility was very low in B cells 
proliferating in response to soluble CD40 ligand, IL-2, and IL-10 (CD40L, Figure 12).51 
Moreover, when we added CD40L to the CpG DNA system (CpG + CD40L), thymidine 
incorporation was enhanced 2-fold compared to the standard CpG DNA system, but 
transducibility became 3.2-fold lower by the mean (P<0.001 by two-sided t test; nine 
independent, paired experiments). By contrast, adding CD40L to the EL-4 B5 system (EL-4 
B5 + CD40L) gave not only slightly increased thymidine incorporation compared to the 
standard EL-4 B5 system, but also 1.3-fold higher B cell transducibility (P<0.05; also nine 
independent, paired experiments). In those experiments in which the B response in the EL-4 
B5 system was relatively weak, addition of CD40L could double the percentage of GFP+ B 
cells. Anti-Ig did not enhance transducibility in the CD40L system, but B cells stimulated 
with CpG DNA only were transducible (about 15% GFP+ cells with monocistronic vector). 
Thus, it appeared that, in particular, B cells stimulated via CD40 in the absence of other T cell 
signals (an artificial condition) somehow resisted transduction by HIV vectors. The vectors 
did not cause elevated surface annexinV expression in CD40L-stimulated than in CpG DNA 
stimulated B cells. Serafini et al. found that in B cells activated via CD40 the transduction 
was blocked at an early stage.57 It is possible that innate cellular defenses, such as 
mechanisms involving TRIM5 or APOBEC3 antiretroviral factors, are involved; they might 
be triggered under certain abnormal cell activation conditions in vivo (possibly mimicked by 
sole CD40L activation).58, 59
 
2.4.3 IL-4 secretion by transduced B cells 
Changes in signal transduction promoted by IL-4 in B cells are summarized on Figure 13. B 
cells transduced with IL-4 encoding vectors, after cell wash, released IL-4 that proved to 
functionally intact during secondary cultures. We studied whether pseudo-transduction played 
a role, i.e., any viral integration-independent effects, including passive transfer of transgene 
proteins by the virus particles (cells become exposed to numerous defective particles).51 
Therefore, we tested viruses produced using packaging constructs with a loss-of-function 
mutant integrase or a vector plasmid (CMV:IL-4-GFP) lacking the central polypurine tract 
(cPPT) involved in nuclear transportation. We added control virus at an MOI of 10 and the 
others, produced in parallel, at concentrations equalized for IL-4 concentrations in the virus-
producer 293T culture supernatant. The control vector gave 13.9% GFP+ B cells (Figure 
14A) and an IL-4 release of 1.1 ng IL-4/105 B cells/24 hours (Figure 14B). The virus lacking 
integrase activity gave only 0.87% GFP+ cells, but no bright GFP+ cells (low MFI), i.e., this 
was pseudo-transduction that weakly occurs with GFP - however this phenomenon is intense 
if membrane-bound transgenic proteins are expressed due to viral budding.51 The IL-4 release 
was also very low; indicating that about 5% of the IL-4 release obtained with the positive 
control may have been due to pseudo-transduction. The virus lacking the cPPT gave 1.92% 
GFP+ cells, including about 1% bright cells. The IL-4 release (6.7-fold lower than control) 
was close to what one would expect for this number of bright GFP+ cells plus pseudo-
transduction as estimated above. Thus, pseudo-transduction played only a negligible role. 
GFP expression and IL-4 secretion were stable in B cells between days 3 and 8 after exposure 
to vector. On day 8 after exposure to vectors with the respective optimal promoters, at an  
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Figure 13. Simplified summary of IL-4-induced signal transduction pathways. 
 
MOI of 10, quantitative PCR revealed multiple copies of GFP DNA per diploid genome in 
CD19+GFP+ B cells (4.8 ± 0.4; means ± 1 SEM, n = 4, i.e., two transduction experiments 
with mono- and two with bicistronic vectors for each cell type and for B cells one of each 
experiment in the CpG and EL-4 B5 systems, data not shown). We obtained overlapping 
results with mono- and bicistronic vectors. We found at least 10-fold lower PCR signals in 
GFP- cells, showing low contamination by DNA plasmids. Since vector-derived episomal 
DNA is short-lived in various cells, including B cells, these data indicate multiple vector 
integration events.57  
 
2.4.4 The secreted transgenic IL-4 is functional 
The B/CpG system used for the transduction of B cells does not support the detection of the 
effects of the secreted transgenic IL-4, especially as it is secreted too late to significantly 
affect B cell fate (transduction is performed on day 2-3, considerable transgene expression 
starts another 48 hours later). However, if the harvested supernatant of such cultures is used as  
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 Figure 14. Correlation between IL-4 secretion and GFP expression in B cells exposed to different 
vector particles: positive control vector (CMV:IL-4-GFP), vector plasmid deleted of the cPPT 
element (‘∆ cPPT’), and virus made using a packaging construct with an inactive mutant integrase 
(‘No integrase’). (A) GFP expression. All three types of vector particles were produced in parallel. 
Control vector CMV:IL-4-GFP was added at an MOI of 10. The other vector particles were added 
at concentrations equalized for the amounts of IL-4 measured in the supernatants of the virus-
producer cells. Upper and lower numbers represent percentages of GFP+ cells and MFI, 
respectively. (B) IL-4 secretion rates measured in this representative experiment (means ± 1 SEM 
of triplicate cultures).  source of IL-4 in secondary cultures (following centrifugation and 0.45µm filtration) IL-4 
ppears to be fully functional. When the supernatant of transduced B cells expressing IL-4- is 
iven to EL4 B5/B cell co-cultures, IgE switch occurs and IgE becomes readily detectible 
data not shown). If the same supernatant is used in CD40L/B cell cultures then the 
roliferation-promoting effect of IL-4 becomes readily measurable by i.e. thymidine-
ncorporation assay (data not shown). None of the above IL-4-related effects were recorded 
hen control supernatants were used – including the supernatant of cells transduced by 
onocistronic vectors encoding GFP alone. 
.4.5 Effects of the bicistronic vector expressing viral FLIP 
e then tested a bicistronic vector expressing FLAG-tagged vFLIP of molluscum 
ontagiosum virus, employing two methods: flow-cytometry and cell-proliferation assay. 
ignal transduction changes triggered by FasL are summarized on Figure 15.50
low-cytometry: B/CpG cultures were transduced on day 2 by monocistronic (CMV:GFP) or 
icistronic (CMV:vFLIP-GFP) lentiviral vectors, then FasL was added on day 5 and GFP+ 
ells were measured on day 7 among viable cells. Transduction was carried out with the 
tilization of an initially low MOI to leave headroom necessary for the anticipated enrichment 
f vFLIP-GFP positive cells. FasL acted as a selection marker for CMV:vFLIP-GFP 
ransduced cells that were enriched among viable cells in the cultures in a dose dependent 
anner. The ratio of living (7AAD negative) GFP+ B cells increased from 4% to 16% if FasL 
as used at 100 ng/ml; and from 4% to 22% if FasL was added at 200 ng/ml (Figure 16). 
his was however not the case for CMV:GFP transduced cells as the living GFP+ B cell 
opulation comprised a stable 7% (6-8%) of the cultures irrespective of FasL concentration 
also showing that lentiviral vector-transduced cells are not sensitive to FasL-triggered  
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Figure 15. Summary of FasL-triggered signal transduction pathways. 
 
apoptosis more than untransduced B cells). Not only did the percentage of the CMV:vFLIP-
GFP cells increase but also their mean fluorescence intensity (data not indicated).  
 Cell-proliferation assay: We added the same bicistronic vector (CMV:vFLIP-GFP) or 
control vector (CMV:GFP) to B cells in the CpG DNA system on day 2 and sorted GFP+ 
cells on day 5 (Figure 17A). We re-cultured the cells in the presence or absence of soluble 
FasL. In three experiments, we measured thymidine incorporation after 48 hours to measure 
cell survival (Figure 17B). Only 14 ± 4% of B cells transduced with control vector, but 63 ± 
12% of B cells transduced with vFLIP vector, resisted killing by FasL. Thus, among those 
cells that could be killed by FasL, 57% (range 45 to 71%) were protected by vFLIP. 
 In B cells transduced in the EL-4 B5 system, intracellular vFLIP was detectable with 
anti-FLAG mAb by FACS and its expression correlated with GFP expression in individual 
cells (Figure 17C). Viral FLIP was also detectable with this antibody by Western blot in 
sorted GFP+, but not in GFP-, B cells (Figure 17D).  
 
2.4.6 Proof of principle for functional lentiviral transduction in the B/CpG system 
In the B/CpG system utilizing late second generation lentiviral vectors we have introduced a 
representative secreted transgene (hu-rIL-4) and an intracellular transgene (vFLIP). Both 
representative genes yielded high amounts of easily detectable transgenic proteins. IL-4 was 
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not only secreted by the GFP marked transduced cells, it also functionally proved to be active 
in secondary cultures using supernatant if the primary cultures containing the secreted hu-rIL-
4 (promoting proliferation or IgE switch depending on the test system). On the other hand 
vFLIP being an intracellular protein, affected only transduced cells also marked by GFP, but 
not other non-transduced cells of the same cultures. As expected vFLIP could efficiently 
rescue the otherwise susceptible GFP+ human primary B cells from FasL-mediated apoptosis 
in a dose-dependent manner (true both for FasL and vFLIP/GFP concentration). 
  
 
22% 4% 16%
7% 6% 8%
<0.3% <0.3% <0.3%
200 ng/ml 100 ng/ml0 ng/ml 
CMV:vFLIP-GFP 
CMV:GFP 
control 
Figure 16. This representative set of experiments shows the protective effect of vFLIP against 
FasL-triggered apoptosis as documented by flow-cytometry. B cells in the CpG system on day 2 
were transduced by low quantities of lentiviruses (CMV:GFP or CMV:vFLIP-GFP) at MOI of 1. 
(The utilization of an initially low MOI low leaves headroom for the enrichment of vFLIP-GFP 
positive cells.) Some cells were not transduced as control cultures. Then 3 days following 
transduction the cells were given different concentrations of FasL (0, 100 or 200 ng/ml) for 48 
hours. Then on day 7 of the culture viable B cells in the gate of living cells (7AAD negative) were 
assayed for GFP expression by flow-cytometry. FasL acted as a selection marker for CMV:vFLIP-
GFP transduced cells that were enriched among viable cells in the cultures in a dose dependent 
manner. This is however not the case for CMV:GFP transduced cells. Not only did the percentage 
of the CMV:vFLIP-GFP cells increase but also their mean fluorescence intensity (data not 
indicated).  
FasL concentration
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 Figure 17. Detection of viral FLIP protein and protection from FasL-induced cell death in B cells 
transduced with vector CMV:vFLIP-GFP. (A) GFP expression in B cells transduced in the CpG DNA 
system with CMV:vFLIP-GFP at an MOI of 10, before and after sorting of GFP+ B cells. Upper and
lower numbers represent percentages of GFP+ cells and MFI, respectively. The gating for the FACS 
sorting is shown by the arrowhead. (B) Sorted GFP+ B cells transduced with CMV:vFLIP-GFP, or 
control vector CMV:GFP, were re-cultured in the presence or absence of FasL then subsequently 
thymidine incorporation was assayed. The black columns represent percentages of cpm relative to 
no-FasL controls (means ± 1 SEM from three independent experiments). Mean cpm in cultures with 
no FasL are also indicated (SEM in parentheses). (C) Detection of intracellular viral FLIP with anti-
FLAG mAb (y axis) and GFP fluorescence (x axis) in B cells transduced with CMV:vFLIP-GFP in the 
EL-4 B5 system. Vector was added on day 3 at an MOI of 10 and cells were analyzed on day 8, 
after 46-fold cell expansion. Percentages of cells stained by anti-FLAG (‘FL’) and of GFP+ cells (‘G’) 
are indicated. (D) Western blot of sorted GFP+ and GFP- B (CD19+) cells transduced as above in 
the EL-4 B5 system, performed with protein equivalents of 3x105 B cells. Stainings with anti-FLAG 
mAb or anti-actin antibodies are shown. Viral FLIP was detected as a band of 34kDa. 
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Future perspectives 
 
 The first section of this PhD thesis demonstrated that we have successfully established 
a human-SCID chimera system for the investigation of EBV-induced post-transplantation 
lymphoproliferative disorder in vivo triggered by endogenous EBV strains of healthy blood-
donors. The resulting chimera system may serve as a model system for EBV reactivation in 
transplanted patients. With the introduction of an active, dominant EBV by performing in vivo 
superinfection we have significantly modified the protocol. This latter method is also a model 
system for post transplantation lymphoproliferative disorders that occur upon infection by 
EBV in an immunologically compromised status. Both systems should be useful for testing 
therapeutic strategies and novel agents in an in vivo system that resembles the human PT-LPD 
syndrome. This stage of drug-trials may be placed between in vitro and human trials as an 
intermediate therapeutic checkpoint.60 Moreover, the combination of EBNA1 qPCR with the 
EBNA6 genomic PCR and RT-PCR assays employed in this work should also be able to 
monitor the peripheral blood EBV load of patients and identify all intrinsic and the 
dominantly active EBV strains, respectively.61, 16, 17, 18, 19  
 Another use of lymphotropic viruses in studying lymphocyte functions is reported in 
the second section of this thesis in the combination of the CpG-DNA motif based human B 
cell monoculture and HIV1-based lentiviral vectors as a to date unique platform for the ex 
vivo assessment of gene function testing and possible gene therapy applications. The 
expressed transgenes proved to be functionally active as seen in functional assays fulfilling 
the ‘proof-of-principle’ both for secreted (IL-4) and intracellular (vFLIP) transgenic proteins. 
Here this second section has joining points with the first section. EBV has now been studied 
for decades, yet even recently novel characteristics of this virus have been discovered i.e. in 
the fields of RNA interference and regulatory T cells. 62, 63, 64, 65 EBV has a vast genome 
encoding numerous genes that interact and reprogram human primary B cells. Therefore, it is 
certain that specific EBV-genes or their combinations are promising candidates for 
investigation in the proposed B/CpG system employing lentiviral vectors. (Although EBV-
derived vectors are also already available for research, their utilization is technically 
demanding and such vectors are unlikely to be inert carriers in such experiments).66, 67, 68
 Due to the special characteristics of lentiviral vectors – the ability to transduce 
differentiated and even resting primary cells (including neurons), stable integration of 
multiple copies into the target cell genome, low toxicity, safety and the relative ease of 
production technique – these vectors have lately been used for the establishment of stable 
transgenic animals.69, 70, 71, 72, 73, 74 Our group – in collaboration with the Agricultural 
Biotechnology Center in Gödöllő – also began to create such animals for research purposes. 
Although the in vivo utilization of lentiviral vectors requires special safety precautions as well 
as concentrated, high quality vector preparations, the collaboration is already fruitful as the 
first transgenic animals have been born: GFP+ Balb/C mice (Figures 18A-B).  
 Combining lentiviral methodology with scFv targeting is a very promising field of 
targeting vector transduction in vivo. In contrast to whole antibodies, an artificially engineered 
scFv is composed of a single protein chain where the originally separately expressed variable 
domains of the light and the heavy chains are connected by a linker amino-acid sequence 
(Figures 19A-B). This allows for simple molecular biology manipulation while preserving 
idiotype specificity. Lentiviral vectors pseudotyped for scFv envelope proteins can selectively 
bind and transduce cells both in vitro and in vivo.75, 76, 77 Specificity is provided by the scFv 
component while efficiency and long-term genetic manipulation are guaranteed by lentiviral 
vectors. In collaboration with other research groups we plan to develop and utilize such 
vectors for research purposes both in vitro and in vivo. 
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Figure 18.  Due to its unique characteristics the lentiviral system may also be used 
in vivo for the establishment of transgenic animals. In collaboration with the group of 
Dr. Zsuzsanna Bősze DSc, Ph.D. we have created GFP+ Balb/C mice via 
pronuclear injection of mouse zygotes. GFP fluorescence may directly be visualized 
in these animals as demonstrated above (Figure 18A shows a GFP transgenic and 
control animals under normal and Figure18B under fluorescent light). 
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Figure 19. Computer images of the structure of an antibody (Figure 19A) and an 
scFv (Figure 19B). An antibody is composed of four protein chains linked by 
disulfide-bonds, whereas an scFv is a single protein chain. 
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Our purpose was to establish a reproducible xeno-
geneic chimera model to observe tumors similar to
the well-known human posttransplant lymphopro-
liferative disease (LPD). First we followed the origi-
nal protocol injecting Epstein-Barr virus positive
(EBV+) human peripheral blood lymphocytes (PBL)
intraperitoneally into immunodeficient (SCID)
mice. Human cells showed T cell phenotype in
majority one week after the transfer, whereas one
month later a shift towards B cell phenotype was
evident according to immunohistochemical and
flow cytometric analysis. At this stage the intraperi-
toneal mass of cells suggested a biologically malig-
nant behaviour infiltrating the liver and the spleen
of the host animal. Immunohistochemistry indicated
proliferating human lymphatic cells expressing EBV
associated proteins and characteristic patterns of
invasion within the affected organs. Eventually LPD
was lethal to the host animals in 46-67 days. Howev-
er, the microscopic appearance of experimental LPD
was different from the human haemopoietic malig-
nancies: the basic structures of lymphatic organs
were preserved and the human T and B cells repop-
ulated the normally T and B dependent areas in
mice. The phenotypes of the proliferating cells were
human and characteristic for the mature T- and B-
lymphocytes. No dominant clone developed during
in vitro culturing of the biologically invasive mass
of cells removed from the tumor-bearing mice. The
results of microscopical, immunological, and flow
cytometrical analysis suggested a mature but uncon-
trolled proliferation of human lymphocytes in SCID
mice. The original method for the induction of post-
transplant LPD in SCID mice was modified in our
further experiments to standardise the experimental
technique increasing the efficiency of B cell prolif-
eration and the reducing the number of unspecific
factors. Subsequent in vivo EBV superinfection was
carried out after the intraperitoneal transfer of a
reduced quantity of human PBL from different
donors. The same disease developed in our modi-
fied chimera model as by the use of original protocol
except for some valuable differences. All hosts
developed LPD regardless the significantly reduced
amount of transplanted PBL and it was lethal in a
shorter period of time (41-43 days) compared to the
original model. The decreased quantity of trans-
planted human lymphatic cells was formerly insuf-
ficient using the original protocol. Therefore this
modified and standardised protocol can lead to a
more predictable and reproducible model allowing
us to examine fine details of posttransplant lympho-
proliferative disease. (Pathology Oncology Research
Vol 6, No 4, 280–286, 2000)
Keywords: SCID mice, lymphoproliferative disease, EBV superinfection, B cell proliferation
Introduction
Epstein, Achong and Barr described first the “Epstein-
Barr virus” (EBV) in 1964.9 EBV is the 4th member of the
herpes virus family (gamma herpesviridae) contains dou-
ble stranded DNA and it is a polyclonal stimulator of 
B-lymphocytes. EBV is a rather ubiquitous infective
agent, 70–90% of the human population is seropositive.5
The causal aetiology of EBV is evident and proved in
some disease, in some others the correlation is revealed by
means of statistics only. Relations to many known human
diseases such as infectious mononucleosis, Burkitt’s lym-
phoma, Hodgkin’s disease, nasopharyngeal carcinoma,
gastric carcinoma and posttransplant lymphoproliferative
disease (LPD) were drawn.32
The LPD may develop in EBV seropositive and immun-
odeficient humans. These immunodeficiencies by origin
can be “natural” (e.g. in AIDS, Duncan’s disease), or
“artificial” (as a result of chronic immunosuppressive
treatment e.g. in posttransplant medication). Among trans-
planted patients the occurrence of LPD is approximately
1%.3 As chronic immunosuppression becomes part of
everyday medicine the problem of LPD grows alike. “Type
A” LPD in younger patients has symptoms similar to infec-
tious mononucleosis and infiltrates organs like the graft,
lymph nodes, bone marrow, liver, gastrointestinal tract,
lungs, heart, nasal pharynx, thyroid glands and the central
nervous system. “Type B” LPD develops in senior patients
in the form of solid tumors within the central nervous sys-
tem and in the liver or elsewhere in the abdomen.7 Both
types are progressive and may be lethal. Biologic behav-
iour generally beats histological grading since the patients
are immunocompromised. Ceasing immunosuppression
usually heals LPD, but simultaneously triggers graft rejec-
tion or the progression of the primary disease. Different
animal models are available for experimental LPD, but the
induction of lymphoid chimeras in genetically immunode-
ficient mice is the most similar to the human disease. The
C.B.17 scid/scid mice were first described in 1983 by
Bosma and were kept inbred ever since. They share a
spontaneous point mutation concerning the centromeric
region of the 16th chromosome. Among the results is a spe-
cial defect of V(D)J recombinase system, namely of the
ligase within the complex.5 Immunoglobulin and T cell
receptor gene rearrangements suffer mistakes, even dele-
tions that remain uncorrected.11 As neither functional B
nor T cells develop, these animals lack specific immune
reactions, are susceptible to infections and can easily host
xenogeneic tissues. There are basically two different
methods to create chimeras by repopulating SCID mice
with human lymphoid cells.15 One involves simultaneous
transfer of human embryonic bone marrow or liver tissue
and human embryonic thymus tissue into infant SCID
mice and the model is often referred to as “SCID-hu”. It
ensures a permanent co-operation of xenogeneic cells.8,14
The other way is to transfer human PBL into mature SCID
mice generally via an intraperitoneal injection and the
model is called “hu-(PBL)-SCID”. Although this method
provides only a transient chimera condition for about six
months, it is convenient and usually stable for a period
enough to examine some human diseases in vivo.8,12,13,14 In
our experiments we used the latter method to create
chimeras and characterised them by immunohistochem-
istry and flow cytometry. Using in vivo superinfection it
was possible to fine-tune and standardise the EBV+ hu-
(PBL)-SCID xenogeneic chimera model reducing unspe-
cific effects of the transplanted cells (e.g. graft versus host
reactions).
Materials and Methods
Mice
C.B.17 scid/scid homozygotic mice were kept inbred in
the animal facility of the University of Pécs, Faculty of
Medicine under specific pathogen free (SPF) conditions.
During the time of experiments the animals were kept in a
laminar cabinet in the Department of Immunology and
Biotechnology. Ciprofloxacin (Ciprobay, Bayer) contain-
ing water was administered per os as antibiotic profilaxis.
Transplantation of human PBL
Buffy-coats from six different blood donors with their
informed consent were the sources of human PBL.
According to attached qualifications both EBV+ and EBV-
buffy-coats were used. A suspension enriched in lympho-
cytes was obtained by density-gradient centrifuging
(20°C, 20 minutes, 2000/min.) over Ficoll solution
(r=1.077 g/cm3). Cell count was completed in Burker
chamber after tripan-blue staining. Intraperitoneal cell
transfers were achieved with 3-6x107 cells according to the
original protocol. Following the modified protocol PBL
was transferred at a smaller quantity that is 1-2x107 cells
per inoculation without changing any other circumstances.
The viability of PBL cells was higher than 98% in all cases.
In vivo superinfection
The B95-8 marmoset cell line (ATCC CRL 1612),
secreting complete infective EB virions was cultured in
DMEM containing 20% FCS for fourteen days in the
Virus Laboratory of the State Office of Public Health,
Pécs, Hungary. Supernatant of the culture was cen-
trifuged (20°C, 5 minutes, 1000/min) and physically fil-
tered through a Whatman GF/C pad before administering
1.5 ml intraperitoneally into the hosts, eleven days after
intraperitoneal PBL transfer. In each of the three pairs of
chimeras created following the modified protocol only
one was subjected to subsequent in vivo superinfection.
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Table 1. Chimeras created following the original proto-
col, mice indicated as “*“ were subjects of early mea-
surements
No. of No. of LPD Survival
mouse donor emergence (days)
1. 1. * *
2. 1. + 55
3. 2. * *
4. 2. + 46
5. 2. + 67
6. 3. * *
7. 3. * *
8. 3. – >122
6. 3. – >122
10. 3. – >122
An extra SCID mouse was given intraperitoneally 1.5 ml
of EBV+ B95-8 supernatant without former PBL transfer
as a negative control.
Antibodies
The following anti-human monoclonal antibodies were
used: anti- CD3, CD4, CD5, CD8, CD10, CD19, CD20,
CD23, CD45, k light chain, l light chain, (all of them from
DAKO, Denmark). Anti-mouse CD45 (IBL-5/25, devel-
oped in our laboratory), a-LMP 1 and MIB-1 (both from
DAKO, Denmark) antibodies were also used.
Immunohistochemistry
Histologic examinations were performed on the intra-
peritoneal lymphoid mass and organs infiltrated by LPD
(liver, spleen) from mice bearing clinical signs of malig-
nant disease. Cryostat slides of frozen organs were fixed in
acetone for 5 minutes then left to air-dry for 2 minutes.
Further reactions were performed in a humidity chamber.
After rehydration with PBS the inhibition of endogenous
peroxidase activity was performed by using phenil-
hydrasin-hydrochloride (1 mg/ml) for 20 minutes. Satura-
tion of the unspecific binding sites with 5% FCS albumin
was completed. Antibodies were incubated for 45 minutes
each on the slides including the streptavidin-peroxidase
conjugated antibody. Signals were developed in a citrate
buffer containing H2O2 and 3-amino-9-ethyl carbasol
(AEC). After 15 minutes development was halted by PBS
solution. Hematoxylin nuclear counter staining was used.
First classical hematoxylin-eosin stain made from all the
samples for microscopic classification of the pathologic
events. Normal human lymphoid tissues and monoclonal
antibodies with irrelevant specificity were used as positive
and negative controls, respectively.
Flow cytometric analysis
FACS phenotype analysis was performed on cells
forming the intraperitoneal mass within LPD bearing
mice and on cells cultured in vitro later on. Centrifuga-
tion (4°C, 5 minutes, 1000/min) following the homo-
genising of the intraperitoneal mass resulted in a suspen-
sion of cells in PBS solution. Cells were incubated with
FITC (fluorescein-isothyocianat) or PE (phycoerythrin)
labelled antibodies for 30 minutes over ice. Measure-
ments were validated by carefully selected positive and
negative controls. FACSCalibur type (Becton Dickinson,
USA) flow cytometer, and the CellQuest software (Bec-
ton Dickinson, USA) were used for analysis.
In vitro culturing
Following sterile biopsy from the affected organs cells
were mechanically dispersed to perform in vitro culturing
over continuous control in DMEM medium containing
10% FCS in a tissue culture thermostat (Forma Scientific,
USA) (37°C, 5% CO2, saturated humidity).
Results
Engraftment of human cells
Using the original protocol we created altogether 10
hu-PBL-SCID xenogeneic chimeras with PBL from
three different human blood donors (Table 1). PBL from
two donors could develop LPD in the mice. In case of the
282 KVELL et al
PATHOLOGY ONCOLOGY RESEARCH
Figure 1. Site of inoculation
prior to LPD, FACS analysis
Figure 3. Origin of periportal
mass of cells, FACS analysis
Figure 4. Phenotype of peripor-
tal mass of cells, FACS analysis
Figure 5. Phenotype of peri-
toenal mass of cells, FACS
analysis
Figure 7. Phenotype of peri-
portal mass of cells, FACS
analysis
Figure 6. Phenotype of peri-
toenal mass of cells, FACS
analysis
Figure 2. Origin of periportal
mass of cells, FACS analysis
third donor no LPD occurred since the person was EBV
seronegative. 
One week after cell transfer at the site of inoculation 
T-lymphocytes were in majority compared to B-lympho-
cytes among human cells, similarly to the phenotype
profile of physiologic human peripheral lymphocytes.
FACS analysis showed the dominance of CD3+ cells
compared to CD19+ cells (Figure 1) isolated from the
peritoneal mass.
LPD formation in the peritoneum
The first sign of the developing LPD was a loosely
structured tissue like mass of cells in the peritoneal cavity,
in our case it was located periportally. The cells prepared
from the peritoneal “tumor-like” mass shared human
CD45+ phenotype according to flow cytometry (Figures
2,3). At this stage of the disease B cells began to prolifer-
ate and formed a dominant subpopulation. Among B cells
some were also CD23+ activated intermediate B cells. The
T cell subpopulation that is in minority by this time is
probably rather CD8+ (Figures 4-7). Immunohistochem-
istry revealed further precious data. The proliferative
capacity of cells that formed the intraperitoneal mass
could be demonstrated by their MIB-1 positivity. Many
cells in a diffuse pattern showed such phenotype indicat-
ing the increased rate of growth (Figure 8). The majority
of tumor forming cells were light chain positive while a
minority showed light chain positive phenotype (Figures
9,10). The presence of the transforming EBV was proved
by the expression of LMP-1 (latent membrane protein type
1) in some human B cells (Figure 11).
Host invasion by LPD
Dissemination of the human lymphatic tissue occurred
during the next stage of LPD in the mouse model. Besides
the lymphoid mass of proliferating cells located in the
hilus of the liver and the spleen macroscopic haemorrhagic
infarcts appeared on the surface of the liver in the mice.
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Figure 8. Intraperitoneal
mass of cells, MIB-1 immuno-
histology, 40x
Figure 9. Intraperitoneal
mass of cells, a-LMP-1 immu-
nohistology, 40x
Figure 10. Intraperitoneal
mass of cells, a-k light chain
immunohistology, 40x
Figure 11. Intraperitoneal
mass of cells, a-l light chain
immunohistology, 40x
Figure 12. Infiltration of the
liver, hematoxilin-eosin stai-
ning, 40x
Figure 13. Infiltration of the
spleen, a-CD20 immunohis-
tology, 100x
Figure 14. Infiltration of the
spleen, a-CD3 immunohisto-
logy, 20x
Figure 15. Infiltration of the
spleen, a-CD20 immunohis-
tology, 20x
Tissue samples of the liver and the spleen were analysed
histologically. Proliferating lymphocytes infiltrating the
tissue regardless of hepatic lobuli were easy to distinguish
from the hepatocellular background after hematoxilin-
eosin staining during microscopic examination (Figure
12). Immunohistochemistry revealed characteristic locali-
sation of human lymphocyte subsets. The CD3+ T cells
preferred periarteriolar lymphatic sheaths (PALS) in the
spleen, while the CD20+ B cells favoured lymphatic folli-
cles (Figures 13-15) similarly to the normal anatomic
location. LPD was lethal to mice in 46-67 days, agony was
accompanied by palpable abdominal tumor, weakness,
hypokinesis and ruffled hair. 
In vitro culturing of tumor cells
Transformed cells removed from the host animals could
be cultured in vitro for approx. 6 weeks. At small magni-
fication colonies formed large spherical groups with many
fission. Based on the findings of flow cytometry besides a
CD19+ phenotype tumor cells also shared and CD5- and
CD10- phenotype meaning that they were B cells but did
not belong to the B1 or centroblast subgroups (Figures
16,17). No dominant clone developed, light chain profile
still favoured the positive population to the positive popu-
lation at a ratio of approx. 3:1 (Figure 18).
Reproducing LPD by using the modified protocol
Using the modified protocol we created altogether 6
chimeras with PBL from three different human blood
donors. Activation by the xenogeneic environment
increased the susceptibility of human lymphocytes to
EBV. In each pair of mice only one was treated with sub-
sequent in vivo superinfection. An extra SCID mouse was
intraperitoneally injected 1.5 ml of B95-8 supernatant as
negative control (Table 2). Note that neither the transfer of
a smaller amount of PBL from EBV seropositive donors
nor the in vivo administration of B95-8 supernatant by
itself caused the emergence of LPD. Only the constellation
of the two mentioned circumstances could create the dis-
ease. In chimeras that received subsequent in vivo super-
infection LPD developed and proved to be lethal in 41-43
days. Palpable abdominal tumor, weakness, hypokinesis
and ruffled hair accompanied their agony. At autopsy of
affected mice an intraperitoneal loosely structured mass of
cells in some ascitic fluid and enlarged, unusually pale
liver and spleen were observed. Flow cytometric analysis
of the intraperitoneal mass of cells showed mainly human
CD45+ phenotype and the dominance of CD19+ B cells
compared to CD3+ T cells (Figures 19-20). The double
negative population contained murine cells (figures not
shown). In vitro cultures of cells removed from the peri-
toneal cavity of moribund LPD hosts showed high capac-
ity for proliferation for over a month before fission halted.
At small magnification colonies formed large spherical
groups of cells adhered to each other after mitosis.
Discussion
There is always uncertainty in creating a hu-PBL-SCID
xenogeneic chimera model. Reproducibility is a major prob-
lem concerning experiments involving biological systems.
According to some literature data, since biological systems
are very complex and sensitive to starting conditions and
non-linear formulas rule them, at the level of present mea-
surement accuracy results can not be forecasted even if start-
ing parameters are clear. The adherence of the graft depends
on many factors that are not clearly understood or cannot be
interfered properly6 (E.g. the graft versus host reaction can
influence the biologic response of the recipient).
The suggested minimal amount of cells required for suc-
cessful transfer, the protocol of preparing a cell suspension
and the treatment of SCID mice prior to transplantation
almost differs in each laboratory. The likelihood of graft
acceptance can be raised with an increase of input cell
quantity and careful protocols that spare cell functions. If
the original protocol is followed for creating hu-PBL-SCID
models the minimally required amount of cells is approx.
5x107 cells per inoculation, smaller quantities usually fail
to successfully repopulate the host.8 Yet we must admit
that increased cell input quantity raises not only the
chances of host repopulation but also points of variation
that lead to unspecific side effects of grafting and unpre-
dictable survival of chimeras.
Since in SCID mice myelopoietic cells develop ade-
quately, intact innate immunity including granulocytes,
monocytes, macrophages and NK cells decrease the prob-
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Figure 16. Phenotype of in
vitro culture, FACS analysis
Figure 17. Phenotype of in
vitro culture, FACS analysis
Figure 18. Clonality of in
vitro culture, FACS analysis
ability of graft adherence and influences LPD as well.
Against murine NK cells an antibody known as anti-asia-
lo GM1 or a sublethal irradiation of 1-4 Gy can be useful.
10
Unfortunately SCID mice are sensitive to irradiation and T
cell lymphomas may emerge. 
According to some experiments not only murine NK
cells, but simultaneously transferred human NK cells can
also decrease the activity of autologous B cells.4 In vitro
activation of human cells prior to transfer may also be
helpful. This can help lymphocyte homing processes too.14
PBL donors can be divided into at least two groups based
on the incidence of LPD. The ability of donors to create
LPD is constant with time and it is characteristic to donors.
Approx. 40% of donors belong to the high incidence group
and 60% to the low-intermediate incidence group. It is an
interesting observation that the number of clones is greater
in LPD developing from PBL of high incidence donors.16
The incidence of LPD in the two groups shows no direct
relation with the concentration of latently infected B cells
in PBL. The frequency of latently infected cells among B-
lymphocytes in the peripheral blood is individual and
varies considerably. In a population of healthy carriers it is
between 5-500x10-7 with a mean of 50x10-7 and is also
characteristic to donors. This low number of latently
infected cells is due to the fact that it concerns only a frac-
tion of memory B cells and can also explain the minimum
amount of cells required for successful repopulation.
Immunosuppression during human allograft transplanta-
tion protocols causes an average 40-50 fold increase of
latently infected B cells in the peripheral blood of patients
as it may perturb mechanisms that regulate the absolute
numbers. Memory cells are unlikely to be under direct
immunosurveillance therefore their increased numbers
must be due to the prolonged survival or increased pro-
duction of precursors that are under direct cytotoxic con-
trol.17 Donors possess different Th1/Th2 cytokine profiles
that influence both graft adherence, B cell proliferation
and the development of graft versus host reactions.1 The
prevalence of CD8+ cells within the graft is various.
Therefore inadequate cytotoxic immunosurveillance may
also play a part in lymphoproliferation. 
EBV subtypes differ in their ability to create LPD, “type
A” EBV is more potent than “type B” EBV.5 The B95-8
marmoset cell line secretes “type A” EBV. Genetic differ-
ences i.e. deletions within the EBNA-2 gene can consider-
ably decrease transforming capacity since almost all viral
promoters contain EBNA-2 dependent elements. The pro-
tein product of the EBNA-2 gene is considered to be a
functional homologue of Notch IC and results in differen-
tiation arrest and continued proliferation. Obviously it is
also a main target of cytotoxic activity.17
Besides the mentioned uncertainties of creating chimera
models, the exact timespan necessary for LPD emergence
can not be forecasted either. In case of an EBV+ PBL
donor the chances of developing LPD in the system with-
in 60-110 days is about 80-100%. The matter is complex
and that means variation is results.
The original method for inducing posttransplant LPD in
SCID mice was modified during our experiments to stan-
dardise and increase the efficiency of B cell tumor occur-
rence with the reduction of unspecific factors. We trans-
ferred a smaller quantity of human PBL compared to the
original protocol and administered EBV from the B95-8
cell line as subsequent in vivo superinfection. These alter-
ations apparently circumvented some points of variation.
The well-documented human LPD developed in the ani-
mals except for some valuable differences. A fraction of
the formerly used cell number of EBV seropositive donors
was sufficient to develop the disease in a slightly shorter
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Table 2. Chimeras created following the modified pro-
tocol, mouse No. 7 was negative control
No. of No. of In vivo LPD Survival
mouse donor infection emergence (days)
1. 1. – – >74
2. 1. + + 41
3. 2. – – >74
4. 2. + + 42
5. 3. – – >74
6. 3. + + 43
7. – + – >74
Figure 19. Phenotype of peri-
toneal LPD, FACS analysis
Figure 20. Phenotype of peri-
toneal LPD, FACS analysis
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Figure 21. Differences between the protocols in the average of
survival and the standard deviation of survival
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and in a more narrow time-span regardless of other donor
characteristics. That is following the modified protocol the
intraperitoneal transfer of 1-2x107 lymphocytes was suffi-
cient to create LPD, average survival decreased from 56 to
42 days and more importantly standard deviation of sur-
vival fell from 10.5 days to 1 day for all three donors. (Fig-
ure 21). Standard deviation describes the reproducibility
of individual measurements and the number of observa-
tions does not influence its value. It is therefore possible to
state that subsequent in vivo superinfection can be a useful
alteration to fine-tune the EBV+ hu-PBL-SCID model and
our modified in vivo model of human LPD can be helpful
in detailing the steps of lymphoproliferation and in testing
new tactics of treating the disease.
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Available online 11 July 2005892Recently, using HIV-1-derived lentivectors, we obtained efficient transduction of primary human B
lymphocytes cocultured with murine EL-4 B5 thymoma cells, but not of isolated B cells activated by
CD40 ligation. Coculture with a cell line is problematic for gene therapy applications or study of
gene functions. We have now found that transduction of B cells in a system using CpG DNA was
comparable to that in the EL-4 B5 system. A monocistronic vector with a CMV promoter gave 32 F
4.7% green fluorescent protein (GFP)+ cells. A bicistronic vector, encoding IL-4 and GFP in the first
and second cistrons, respectively, gave 14.2 F 2.1% GFP+ cells and IL-4 secretion of 1.3 F 0.2 ng/105
B cells/24 h. This was similar to results obtained in CD34+ cells using the elongation factor-1A
promoter. Activated memory and naive B cells were transducible. After transduction with a
bicistronic vector encoding a viral FLIP molecule, vFLIP was detectable by FACS or Western blot in
GFP+, but not in GFP, B cells, and 57% of sorted GFP+ B cells were protected against Fas ligand-
induced cell death. This system should be useful for gene function research in primary B cells and
development of gene therapies.Key Words: HIV-1-derived lentivectors, bicistronic vectors, human primary B lymphocytes,
CpG DNA, viral FLIPINTRODUCTION
Optimization of methods for gene delivery into primary
human cells is important for research on gene functions
and development of gene therapies [1]. Gene transfer into
primary human B lymphocytes has been notoriously
difficult. Successful applications of nonviral methods to
functional assays of transgenes have not been reported
for these cells. Epstein–Barr virus vectors so far have been
tested only in B cell lines [2]. Murine oncoretroviral
vectors gave low transduction efficiency (of up to about
4%) in primary human B cells; they could be utilized to
study effects detectable by very sensitive methods, such
as immunoglobulin (Ig) class-switch recombination
detectable by PCR [3]. HIV-1-derived lentivectors gave
efficient transduction of various immature and mature
human hematopoietic cells [4–6]. Transgene expression
restricted to B lymphocytes was obtained by grafting
lentivector-transduced CD34+ progenitors into NOD/
SCID mice [7]. T lymphocytes could be transduced after
activation, at least from the G0 to the G1 stage of the cell
cycle [5,6]. But primary human B cells activated intoproliferation by crosslinking of CD40 in the presence of
various cytokines were very poorly transducible [8,9].
Recently with such vectors we obtained efficient trans-
duction of primary B cells cocultured with irradiated
murine EL-4 B5 thymoma cells; monocistronic vectors
with the human cytomegalovirus (CMV) or elongation
factor-1a (EF-1a) internal promoter gave 27 F 12% green
fluorescent protein (GFP)+ cells [9].
For gene therapy applications, however, a cell line
potentially adds risks, such as generation of recombinant
viruses. For studies of gene functions a handicap is that
the functions of the thymoma cells have not yet been
molecularly characterized. The first aim of this study was
to find a culture system for transduction with HIV vectors
of isolated B cells activated by defined stimuli. The LPS
receptor, Toll-like receptor-4 (TLR4), is lacking in human
B cells. But TLR9, the endosomal receptor for bacterial
DNA (short single-stranded DNA containing nonmethy-
lated CpG motifs; CpG DNA), is constitutively expressed
in memory human B cells and rapidly upregulated by
anti-Ig antibody—which mimics an antigen signal—inMOLECULAR THERAPY Vol. 12, No. 5, November 2005
Copyright C The American Society of Gene Therapy
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ARTICLEdoi:10.1016/j.ymthe.2005.05.010naRve B cells [10,11]. We report here efficient lentiviral
transduction of B cells cultured with CpG DNA, anti-Ig,
IL-2, and IL-10.
The second aim was to test bicistronic HIV vectors
encoding the transgene in the first cistron and GFP in the
second cistron, downstream of the internal ribosomal
entry site (IRES). The vectors contained the woodchuck
hepatitis virus posttranscriptional regulatory element
(WPRE) [12]. First, we tested a cytokine gene; this allows
quantitation of secreted protein. IL-4 was chosen because
it was produced neither by B cells nor in our CD34+ cell-
derived cultures. CD34+ hematopoietic cells were utilized
as a primary cell control known to be transducible with
various HIV vector constructs [13,14]. As shown below,
with the IL-4 vector using the CMV promoter the
cytokine secretion rate of B cells was comparable to that
of CD34+-derived cells transduced by this vector with the
EF-1a promoter. Second, we tested a viral FLIP gene. Viral
FLIP proteins, like the short isoform of cellular FLIP,
competitively replace the caspase in the proximal signal-
ing complex that forms after the ligation of death
receptors, such as Fas [15]. Thus, transduction should
produce a positive (survival enhancing) effect rather than
a loss of function readout only. Such an effect was
obtained in Fas ligand (FasL)-exposed B cells.
RESULTS AND DISCUSSION
B Cell Transduction in a Culture System Using CpG
DNA
We found that peripheral blood B cells stimulated by
CpG DNA, anti-Ig antibody, and the cytokines IL-2 andFIG. 1. GFP MFI in B cells transduced with monocistronic or bicistronic HIV vector
cultured in the CpG DNA system. Virus particles for the indicated vectors were ad
viable cells on day 6. 2-D plots show staining with PE-anti-CD19 mAb on the y axi
of these cells are indicated by upper and lower numbers, respectively, in the his
MOLECULAR THERAPY Vol. 12, No. 5, November 2005
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transduced by HIV vectors. For monocistronic (GFP) and
bicistronic (IL-4–IRES–GFP) vectors, the mean fluores-
cence intensity (MFI) of GFP+ B cells was always higher
(2.5-fold or more) with the CMV than with the EF-1a
internal promoter (Fig. 1), confirming our previous
findings with monocistronic vectors [9]. As expected,
the percentages of GFP+ cells were lower with the
bicistronic compared to the monocistronic vectors (3-
or 2.3-fold by the mean, respectively, for the EF-1a or
CMV promoter; for the CMV promoter, mean data are
shown in Fig. 2, CpG).
The CG-rich oligonucleotides C274 (21 bases) and
2006 (24 bases), which caused optimal B cell proliferation
in the study by Marshall et al. [16], both allowed for
efficient transduction, whereas oligonucleotide C661,
with all CG inverted to GC, gave 20-fold lower prolifer-
ation and transduction. Vectors had to be added to the B
cell cultures on day 2 or later. At a multiplicity of
infection of 20 HeLa cell-transducing units per B cell
(m.o.i. of 20) the numbers of GFP+ cells were 1.2-fold
higher by the mean than at an m.o.i. of 10, but at an
m.o.i. of 30 or higher the numbers progressively
decreased. We also found this both with vector particles
added to culture plates by low-speed centrifugation at
1000g and with the particles left in the supernatant,
whereas virus-free supernatant of the virus-producer cells
showed no toxicity. In B cells, exposure to vector caused
increase in annexin V+ cells (on day 4, from 13% in
control culture to 28% in culture with virus added on day
3 at an m.o.i. of 80), indicating that apoptosis was
involved. Our vectors were not toxic for T cells ands was higher with the CMV than with the EF-1a internal promoter. B cells were
ded to parallel cultures on day 3 at an m.o.i. of 10. FACS analysis was done in
s (isotype controls gave b0.5% background). Percentages of GFP+ cells and MFI
tograms.
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FIG. 2. Differences in B cell transducibility by HIV vectors under various culture
conditions. Vectors CMV:GFP or CMV:IL4-GFP were added on day 3 (m.o.i. o
10) to the CD40L system (CD40L), CpG DNA system (CpG), CpG DNA system
in the presence of CD40L (CpG + CD40L), EL-4 B5 system (EL-4 B5), or EL-4
B5 system in the presence of CD40L (EL-4 B5 + CD40L). FACS analysis wa
done in viable cells on day 6 or 7. Shown are means F 1 SEM for percentage
of GFP+ B cells from nine independent experiments for each culture condition
Transduction in CpG versus CpG + CD40L, and in EL-4 B5 versus EL-4 B5 +
CD40L, was compared in parallel experiments. Significant, opposite effects o
CD40L on transducibility were found with both vectors (**P b 0.001; *P b
0.05; by two-sided t test).
ARTICLE doi:10.1016/j.ymthe.2005.05.010
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s
s
.
fCD34+ cells. This may reflect the fact that, in general, B
cells are more prone to apoptosis in culture than many
other cells.
Comparison of Different B Cell Culture Systems
Viable cell expansion in the CpG DNA system set up
with total peripheral blood B cells was fivefold by the
mean in 10 days. Individual B cells proliferate very
heterogeneously in this system [10]. At least fivefold
higher B cell expansion was obtained in the system using
EL-4 B5 murine thymoma cells as helper T cells [9,17].
But the percentages of transduced B cells among the
viable cells analyzed on day 6 or 7 were very similar in
both systems (Fig. 2, CpG and EL-4 B5; there were about
30 and 14% GFP+ cells, respectively, for vectors
CMV:GFP and CMV:IL4-GFP). Since activated B cells
proliferated and outnumbered nonproliferating cells,
this means that proliferating B cells were similarly
transduced in both systems. Various cell types, e.g., T
cells [5,6], after some activation become transducible
with lentivectors even if they do not divide. So far this
could not be studied with B cells, because—unlike T
cells—B cell populations could not be maintained in an
activated, nondividing state.
In agreement with our previous data [9], however,
transducibility was very low in B cells proliferating in
response to soluble CD40 ligand, IL-2, and IL-10 (CD40L,
Fig. 2). Moreover, when we added CD40L to the CpG
DNA system (CpG + CD40L), thymidine incorporation
was enhanced 2-fold compared to the standard CpG DNA
system, but the transducibility became 3.2-fold lower by
the mean ( P b 0.001 by two-sided t test; nine independ-ent, paired experiments). By contrast, adding CD40L to
the EL-5 B5 system (EL-4 B5 + CD40L) gave not only
slightly increased thymidine incorporation compared to
the standard EL-4 B5 system, but also 1.3-fold higher B
cell transducibility ( P b 0.05; also nine independent,
paired experiments). In those experiments in which the B
response in the EL-4 B5 system was relatively weak,
addition of CD40L could double the percentage of GFP+ B
cells. In addition we found that CD40L enhanced B
transduction in total peripheral blood lymphocytes
stimulated with pokeweed mitogen. Anti-Ig did not
enhance transducibility in the CD40L system, but B cells
stimulated with CpG DNA only were transducible (about
15% GFP+ cells with monocistronic vector).
Thus, it appeared that, in particular, B cells stimulated
via CD40 in the absence of other T cell signals (an
artificial condition) somehow resisted transduction by
HIV vectors. The vectors did not cause more annexin V
expression in CD40L-stimulated than in CpG DNA-
stimulated B cells. Serafini et al. [18] found that in B cells
activated via CD40 the transduction was blocked at an
early stage. It is possible that innate cellular defenses,
such as mechanisms involving TRIM5 or APOBEC3
antiretroviral factors [19,20], are involved; they might
be triggered under certain (abnormal?) cell activation
conditions in vivo.
Transduction of Naive and Memory B Cells
In accordance with published data [10,11], anti-Ig
enhanced the proliferation of naRve (CD27), but not
of memory (CD27+), B cells in the CpG DNA system
(2.9-fold by the mean; Fig. 3A). Even with anti-Ig,
proliferation was 2.1-fold lower in naive than in
memory B cultures. However, after 7 days of culture
the majority of naive B cells expressed CD27, and in
cultures with vector these cells expressed GFP very
similar to memory B cells (Fig. 3B shows data represen-
tative of two other independent experiments). CD27 is
an activation marker for naive B cells [21]. The naive B
cells that remained CD27 were not transduced. On the
other hand, cultures set up with memory B cells always
contained some CD27 cells after culture, but these cells
were transduced. Since some B cells express CD27 ligand
[21], these may have been cells with ligand-modulated
CD27. In any case, the data show that activated naive
and memory B cells were transducible in the CpG DNA
system.
IL-4 Secretion by Transduced B Cells
B cells transduced with IL-4 vectors, after cell wash,
released IL-4 during secondary culture. We studied
whether pseudotransduction (PTD) played a role, i.e.,
any viral integration-independent effects, including pas-
sive transfer of transgene proteins by the virus particles
(cells become exposed to numerous defective particles)
[9]. Therefore, we tested viruses produced using a pack-MOLECULAR THERAPY Vol. 12, No. 5, November 2005
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FIG. 3. Naive and memory B cells proliferated and were transducible in the CpG DNA system. (A) Anti-Ig antibody (aIg) enhanced thymidine incorporation by
naive (CD27, white columns), but not by memory (CD27+, black columns), B cells in the presence of CpG DNA, with or without IL-2 and IL-10 (meansF 1 SEM
of counts per minute (cpm) from three independent experiments). (B) The 2-D plots show CD27 expression and FL1 fluorescence in sorted memory and naive B
cells before (Day 0) and after culture in the CpG DNA system (Day 7), with no virus or with vector CMV:GFP added on day 3 an m.o.i. of 10. Percentages of
CD27+ cells (27+) and of GFP+ cells among the CD27+ cells (27+GF+) are indicated (experiment representative for three independent experiments). Only those
naive B cells that became CD27+ were transduced.
ARTICLEdoi:10.1016/j.ymthe.2005.05.010aging construct with a loss-of-function mutant integrase
or a vector plasmid (CMV:IL4-GFP) lacking the central
polypurine tract (cPPT) involved in nuclear translocation
[22]. We added control virus at an m.o.i. of 10 and the
others, produced in parallel, at concentrations equalized
for IL-4 concentrations in the 293T culture supernatant.
Control vector gave 13.9% GFP+ B cells (Fig. 4A) and an
IL-4 release of 1.1 ng IL-4/105 B cells/24 h (Fig. 4B). The
virus lacking integrase activity gave 0.87% GFP+ cells, but
no bright GFP+ cells, i.e., this was weak PTD that occurs
with GFP [9]. The IL-4 release was low, indicating that
about 5% of the IL-4 release obtained with the positive
control may have been due to PTD. The virus lacking the
cPPT gave 1.92% GFP+ cells, including about 1% bright
cells. The IL-4 release (6.7-fold lower than control) was
close to what one would expect for this number of bright
GFP+ cells plus PTD as estimated above. Thus, PTD played
a negligible role.
Comparison of IL-4 Secretion by B Cells and CD34+
Cells
We used CD34+ cells as a reference for work with
lentivectors. After transduction with the IL-4 vector with
the EF-1a promoter, which is optimal in these cells [13],
the GFP expression in CD34+ cell-derived cultures (Fig. 5A;
the upper histograms) was similar to that obtained in BMOLECULAR THERAPY Vol. 12, No. 5, November 2005
Copyright C The American Society of Gene Therapycells with vector CMV:IL4-GFP. In CD34+-derived cells,
intracytoplasmic IL-4 was detectable by FACS and corre-
lated with GFP expression among individual transduced
cells (lower histograms in Fig. 5A). Although B cells do
not produce IL-4 [23], a strong nonspecific staining by
the anti-IL-4 antibody in transduced and nontransduced
B cells made such detection impossible. IL-4 secretion was
also similar in B cells and CD34+-derived cells (Fig. 5B;
about 1.2 ng IL-4/105 cells/24 h). In B cells, IL-4 secretion
with the EF-1a promoter was 3.4-fold lower than with the
CMV promoter. In FACS-sorted GFP+ B cells, the IL-4
secretion increased in parallel with their enrichment (not
shown). Thus, transducibility with bicistronic vector was
similar for B and CD34+ cells. That many B cells become
secretory cells (plasma cells) was apparently not relevant
for the cytokine secretion rate. However, a considerably
lower cytokine secretion rate was reported for primary B
leukemia cells transduced with a bicistronic HIV vector
lacking the WPRE [24]. This element enhances mRNA
stability [12].
GFP expression and IL-4 secretion were stable in B cells
between days 3 and 8 after exposure to vector and in
CD34+-derived cells when followed up for 21 days. On
day 8 after exposure to vectors with the respective
optimal promoters, at an m.o.i. of 10, quantitative PCR
revealed multiple copies of GFP DNA per diploid genome895
FIG. 4. Correlation between IL-4 secretion and GFP expression in B cells exposed to different vector particles: positive control vector (CMV:IL4-GFP), vecto
plasmid deleted of the cPPT element (D cPPT), and virus made using a packaging construct with an inactive mutant integrase (No integrase). (A) GFP expression
All three types of vector particles were produced in parallel. Control vector CMV:IL4-GFP was added at an m.o.i. of 10. The other vector particles were added a
concentrations equalized for the amounts of IL-4 measured in the supernatants of the virus-producer cells. Upper and lower numbers represent percentages o
GFP+ cells and MFI, respectively. (B) IL-4 secretion rates measured in this representative experiment (means F 1 SEM of triplicate cultures).
ARTICLE doi:10.1016/j.ymthe.2005.05.010in CD34+-derived GFP+ cells (4.5 F 0.3), as expected [25],
and also in CD19+GFP+ B cells (4.8 F 0.4; meansF 1 SEM,
n = 4, i.e., two transduction experiments with mono- and
two with bicistronic vectors for each cell type and for B
cells one of each experiment in the CpG and B5 systems).FIG. 5. GFP expression and IL-4 secretion by B cells transduced with vector CMV:IL4-GFP were similar to those found in cell cultures derived from cord blood
CD34+ cells transduced with vector EF1a:IL4-GFP. (A) The upper plots show GFP expression in cell culture derived from 97% pure cord blood CD34+ cells from a
representative experiment. EF1a:IL4-GFP was added on day 1 at an m.o.i. of 20; cells were analyzed on day 5. Upper and lower numbers represent percentage
of GFP+ cells and MFI, respectively. The lower plots show a staining with PE–anti-IL-4 mAb on the y axis and GFP fluorescence on the x axis on day 5. Percentage
of cells stained by anti-IL-4 (
,,
IL
,,
),and of GFP+ cells (
,,
G
,,
) are indicated. (B) IL-4 secretion rates measured in B cells and CD34+ cell-derived cultures transduced
with the indicated vectors at an m.o.i. of 10 (means F 1 SEM from six independent experiments).
MOLECULAR THERAPY Vol. 12, No. 5, November 2005896
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t
fWe obtained overlapping results with mono- and bicis-
tronic vectors. We found at least 10-fold lower PCR
signals in GFP cells, showing low contamination by
DNA plasmids. Since vector-derived episomal DNA is
short-lived in various cells, including B cells [18], theses
sy
ARTICLEdoi:10.1016/j.ymthe.2005.05.010data indicate multiple vector integration in both cell
types.
Effects of Bicistronic Vector Expressing Viral FLIP
We then tested a bicistronic vector expressing FLAG-
tagged vFLIP of molluscum contagiosum virus [15]. We
added this vector (CMV:vFLIP-GFP) or control vector
(CMV:GFP) to B cells in the CpG DNA system on day 2
and sorted GFP+ cells on day 5 (Fig. 6A). We recultured
the cells in the presence or absence of soluble FasL. In two
experiments, transduction of vFLIP caused a 1.8- to 2.4-
fold reduction in the number of FasL-induced annexin V+
apoptotic cells after 20 h (without and with FasL,
respectively, there were 32 F 3.9 and 79 F 5.6% annexin
V+ cells for control vector versus 35F 4.4 and 57F 1.5 forFIG. 6. Detection of viral FLIP protein and of protection from FasL-induced cell d
cells transduced in the CpG DNA system with CMV:vFLIP-GFP at an m.o.i. of 10
percentages of GFP+ cells and MFI, respectively. The gating for the FACS sorting i
transduced with CMV:vFLIP-GFP, or control vector CMV:GFP, after reculture in t
counts per minute (cpm) relative to no-FasL controls (means F 1 SEM from three
(SEM in parentheses). (C) Detection of intracellular viral FLIP with anti-FLAG mAb (
in the EL-4 B5 system. Vector was added on day 3 at an m.o.i. of 10 and cells were
anti-FLAG (
,,
FL
,,
) and of GFP+ cells (
,,
G
,,
) are indicated. (D) Western blot of sorte
performed with protein equivalents of 3  105 B cells. Stainings with anti-FLAG m
kDa.
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thymidine incorporation after 48 h to detect cell survival
(Fig. 6B). Only 14 F 4% of B cells transduced with control
vector, but 63 F 12% of B cells transduced with vFLIP
vector, resisted killing by FasL. Thus, among those cells
that could be killed by FasL, 57% (range 45 to 71%) were
protected by vFLIP.
In B cells transduced in the EL-4 B5 system, intra-
cellular vFLIP was detectable with anti-FLAG mAb by
FACS and its expression correlated with GFP expression
in individual cells (Fig. 6C). Viral FLIP was also detectable
with this antibody by Western blot in sorted GFP+, but
not in GFP, B cells (Fig. 6D).
In conclusion, with an HIV-1-derived bicistronic
vector we obtained proof of principle for the testing ofeath in B cells transduced with vector CMV:vFLIP-GFP. (A) GFP expression in B
, before and after sorting of GFP+ B cells. Upper and lower numbers represent
s shown by the arrowhead. (B) Thymidine incorporation by sorted GFP+ B cells
he presence or absence of FasL. The black columns represent percentages of
independent experiments). Mean cpm in cultures with no FasL are indicated
y axis) and GFP fluorescence (x axis) in B cells transduced with CMV:vFLIP-GFP
analyzed on day 8, after 46-fold cell expansion. Percentages of cells stained by
d GFP+ and GFP B (CD19+) cells transduced as above in the EL-4 B5 system,
Ab or anti-actin antibodies are shown. Viral FLIP was detected as a band of 34
897
ARTICLE doi:10.1016/j.ymthe.2005.05.010a gene function in primary human B cells. The CpG DNA
culture system should be useful for such studies.
MATERIALS AND METHODS
HIV-1-Derived Vectors
A second-generation packaging system and self-inactivating HIV-1
vectors [26] with the pLoxP site in the 3VLTR [27] were utilized. The
monocistronic vector with the EF-1a internal promoter (called vector
EF1a:GFP in this study) was plasmid pWPT-GFP for which the map and
sequence are available at http://www.tronolab.unige.ch. This plasmid
carries, in the 5V to 3V direction, the cPPT element [22], the intronless
(bshortQ) EF-1a promoter, the expression cassette, and the WPRE [12].
Vector CMV:GFP was made by replacing the promoter with the human
CMV promoter [13] between the ClaI and the BamHI restriction sites. In
the bicistronic vectors, which were derived from the above vectors, the
first cistron was the transgene of interest, between the BamHI and the
SalI restriction sites, followed by the encephalomyocarditis virus IRES
[27] and GFP encoded downstream of the IRES. In the vectors EF1a:IL4-
GFP and CMV:IL4-GFP the transgene was the complete human IL-4
cDNA sequence (a kind gift from Dr. J.-F. Gauchat, formerly at the
Institut Pierre Fabre, St. Julien, France). In vector CMV:vFLIP-GFP the
transgene was the FLAG-tagged viral FLIP of human molluscum
contagiosum virus (open reading frame 159L), kindly provided by Dr.
Margot Thome of the Department of Biochemistry, University of
Lausanne [15]. In some experiments we used a vector plasmid as above,
except that it lacked the cPPT element, or a packaging construct [9]
with a loss-of-function mutant integrase (mutation D64V) [28].
Virus particles pseudotyped with vesicular stomatitis virus G glyco-
protein were produced, concentrated 100-fold by ultracentrifugation, and
titrated on HeLa cells by measurement of GFP+ cells by FACS to establish
HeLa transducing units per milliliter (usually 0.5 to 2  108), as described
[9]. Viral stocks were suspended in B cell culture medium and stored at
708C.
Cell Cultures and Transduction
Approval for research on human cells was obtained from the Ethics
Committee of the Geneva University Hospitals. Written consent was
provided for all cell samples. B cells were isolated to more than 99% purity
from buffy coats of virus-screened blood donations obtained from the
Geneva Transfusion Center using Ficoll–Hypaque centrifugation and anti-
CD19 magnetic beads (Dynal) [29]. All B cell cultures were grown in RPMI
1640 medium supplemented with 10% fetal calf serum, 2-mercaptoetha-
nol, Hepes buffer, and antibiotics as described [29].
CpG DNA system. B cells (25,000 cells/200 Al culture; flat-bottom 96-
well plates) were stimulated with CpG DNA (2.5 Ag/ml), anti-Ig
antibody (2 Ag/ml), IL-2 (50 ng/ml), and IL-10 (10 ng/ml). CpG
oligonucleotides of the published sequences C274, 2006, and C661
[16] were obtained as complete phosphorothioates synthesized to our
order by Microsynth (Balgach, Switzerland). Anti-Ig was goat F(abV)2
anti-human IgA + IgG + IgM (H+L) (Jackson ImmunoResearch). The
cytokines were from PeproTech. FACS sorting of CD27+/CD27 cells
was done as described [29].
CD40L system. B cells (50,000 cells/200 Al) were stimulated with a soluble
oligomeric CD40L (300 ng/ml), IL-2 (50 ng/ml), and IL-10 (10 ng/ml) as
described [29]. When CD40L was added to the CpG DNA system or the EL-
4 B5 system, its concentration was also 300 ng/ml.
EL-4 B5 system. B cells (3000 cells/200 Al) were stimulated with 50,000
irradiated EL-4 B5 murine thymoma cells and a mixture of human
cytokines acting on the EL-4 B5 cells (IL-1h) or the B cells (TNF-a, IL-2,
and IL-10), as described [9].
To transduce B cell cultures at different times, the big cell clusters,
which formed in all culture systems, were dispersed by gentle pipetting
(five times aspiration of the culture using 200-Al tips). Virus particles were
then added to the cultures in a volume of 2 to 4 Al, at the indicated m.o.i.
according to cell counts by microscope (B cells or B plus EL-4 B5 cells),898without further manipulations or cell wash. We found that centrifugation
of virus particles in new culture plates (spinoculation) with cell transfer
did not give better results.
CD34+ cell culture and transduction. Umbilical cord blood CD34+ cells
were isolated to N95% purity with anti-CD34 magnetic beads (Dynal),
cultured, and transduced as described [13]. Briefly, the cells (105/200 Al)
were first cultured and transduced on day 1 in the presence of
thrombopoietin (TPO). After 48 h, the cells were recultured in Iscove’s
modified Dulbecco’s medium supplemented with 10% fetal calf serum,
antibiotics, TPO, Flt3-ligand, and stem cell factor; the cells were
recultured every 6 days.
Sorting and FACS Analysis of Transduced Cells
Various GFP+ cell populations were sorted on a FACStar sorter, and
analyses of GFP+ cells were performed on a FACScan analyzer using
CellQuest software (Becton–Dickinson), at the cytofluorometry laboratory
of the Geneva Medical Center. Cells were pretreated with polyclonal
mouse Ig before staining with phycoerythrin (PE)-coupled anti-CD19 [9],
anti-CD27 [29], or anti-CD34 [13] mAb, and viable (7-amino-actino-
mycin-D low) cells were gated for analysis of GFP expression [9]. For
analysis of cytoplasmic IL-4, cells were cultured with brefeldin A (Sigma),
2.5 Ag/ml, for 3 h. For analysis of cytoplasmic IL-4 or viral FLIP, cells were
treated with Cytofix/Cytoperm and Perm/Wash solutions, followed by
AB+ serum, and then stained, respectively, with PE-coupled anti-IL-4 mAb
(Pharmingen) or anti-FLAG-M2 mAb (Sigma), which we coupled to biotin,
followed by PE-coupled streptavin (Jackson ImmunoResearch). The
isotype control was mouse IgG1. Apoptosis was assessed using the
Annexin V–PE Apoptosis Detection Kit I (Becton–Dickinson).
Other Analyses of Transduced Cells
IL-4 secretion rate. On day 2 or 3 after addition of viral particles, B cells or
CD34+ cells were harvested and washed twice in culture medium in
Eppendorf tubes, and viable, trypan blue-excluding cells were counted.
The cells were recultured as before, and after 24 h soluble IL-4 was
measured in culture supernatants by Quantikine Human IL-4 Immuno-
assay (R&D Systems).
Real-time quantitative PCR. The LightCycler system, High Pure PCR
Template Preparation Kit, and LightCycler FastStart DNA MasterPLUS SYBR
Green I kit (all from Roche) were utilized. Cells were transduced with
vectors treated with DNase I before ultracentrifugation [7]. PCR was
performed in separate assays for genomic DNA, using intron-binding
primers for h2-microglobulin (5V-GGCACTGCTGAGATACTGAT-3V,
reverse 5V-GCTAGGACAGCAGGACTTA-3V; 215-bp product) and for vector
DNA, using GFP primers (5V-GGCAAGCTGACCCTGAAGTT-3V, 5V-
GCATGGCGGACTTGAAGAAGT-3V; 149-bp product); respective plasmid
standards were utilized.
FasL assay. GFP+ cells were sorted 3 days after exposure to vector and
recultured (20,000 trypan blue-excluding cells/200 Al, triplicate cultures)
in the CpG DNA system (without anti-Ig) in the presence of soluble
oligomeric FasL (200 ng/ml) prepared as described [30]. Thymidine
incorporation was measured after 48 h including the pulsing during the
last 12 h [29] with 1 ACi (0.037 MBq) [methyl-3H]thymidine (Amersham
Pharmacia Biotech).
Western blot for viral FLIP. This was done with the ECL Western blotting
analysis system (Amersham) using 0.45-Am nitrocellulose membranes
(Bio-Rad) and Biomax chemiluminescence films (Kodak). The antibodies
were IgG1 mouse anti-FLAG-M2 mAb (Sigma) or polyclonal goat IgG anti-
actin (Santa Cruz Biotechnologies) in conjunction with horseradish
peroxidase-coupled anti-mouse or anti-goat antibodies, respectively
(Santa Cruz Biotechnologies).
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